
==== Front
J Exp Clin Cancer Res
J Exp Clin Cancer Res
Journal of Experimental & Clinical Cancer Research : CR
0392-9078
1756-9966
BioMed Central London

39218911
3166
10.1186/s13046-024-03166-w
Review
Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer – a comprehensive review
Reese Kim-Lea
Pantel Klaus pantel@uke.de

Smit Daniel J. d.smit@uke.de

https://ror.org/01zgy1s35 grid.13648.38 0000 0001 2180 3484 Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, 20246 Germany
2 9 2024
2 9 2024
2024
43 25018 3 2024
16 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.

Keywords

Blood-based biomarkers
Early-stage diagnosis
Liquid biopsy
Multimarker panel
Pancreatic cancer
Universitätsklinikum Hamburg-Eppendorf (UKE) (5411)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Italian National Cancer Institute ‘Regina Elena’ 2024
==== Body
pmcBackground

The most common type of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all pancreatic cancers [1]. PDAC-related precancerous conditions include pancreatic intraepithelial neoplasms (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs). The etiology of pancreatic cancer is not fully understood, but several risk factors are associated with PDAC. In addition to common cancer risk factors, including age, obesity, genetic predispositions, smoking and alcohol consumption, the factors conferring the highest risk are type 2 diabetes mellitus and chronic pancreatitis [2].

Pancreatic cancer is the seventh most commonly diagnosed cancer and the fourth most frequent cause of cancer-related deaths in Europe; it accounted for almost as many diagnoses (140,116 cases) as deaths (132,134 deaths) in 2020 [3]. Despite tremendous efforts in research and new therapies resulting in increased survival rates of patients with other cancer types, pancreatic cancer still has a low 5-year survival rate of approximately 10%, with a median overall survival (OS) of less than six months [4]. One of the main reasons is late diagnosis, as patients do not show specific early clinical symptoms [5]. At the time of PDAC detection, less than 20% of tumors are eligible for curative resection [6]. However, surgery followed by adjuvant systemic chemotherapy is the best therapeutic option, significantly increasing the 5-year survival rate [7]. At advanced tumor stages with metastases, the only remaining treatment is systemic chemotherapy, which has a low response rate and a high resistance rate [6]. Consequently, it is highly important to develop diagnostic tests that enable the detection of early-stage PDAC (AJCC/UICC stages I and II) to improve the OS and progression-free survival (PFS) of patients.

PDAC is mainly diagnosed through medical imaging methods, including computer tomography, magnetic resonance imaging, magnetic or endoscopic retrograde cholangiopancreatography, and endoscopic ultrasound-guided fine needle aspiration. However, a clear diagnosis is not always possible because of the retroperitoneal location of the pancreas and the small size of early-stage PDAC lesions [6, 8]. In addition, screening for the early diagnosis of PDAC by imaging is not practical, as it is neither cost nor time efficient and involves exposure to radiation [8].

Liquid biopsy (LB) is a minimally invasive procedure that allows the sampling and analysis of body fluids, thus enabling cancer diagnosis, treatment monitoring, surveillance, and prognostication [9]. The samples can be obtained from various body fluids, including urine, saliva, cerebrospinal fluid, bone marrow, or blood [10]. In recent years, blood has been one of the most popular analytes, as blood sampling is easy, cost-effective, and repeatable [11]. Biomarkers that can be detected in the blood include circulating tumor cells (CTCs), circulating host cells, including cancer-associated fibroblasts (CAFs) or circulating endothelial cells (CECs), circulating cell-free RNA and DNA (cfRNA, cfDNA), extracellular vesicles (EVs) and proteins [12] (Fig. 1). However, to date, no single biomarker or multimarker panel can reliably diagnose PDAC, especially in the early stages.Fig. 1 Overview of (blood-based) liquid biopsy analytes for the early detection of pancreatic cancer. The figure was created with BioRender.com under academic license

In this review, we summarize potential biomarkers and detection methods for blood-based liquid biopsy and discuss their implications for the early-stage detection of PDAC. Moreover, we review publications on multibiomarker panels for PDAC diagnosis and highlight their importance in the early diagnosis of pancreatic cancer.

Methods

The literature search for this narrative review regarding multibiomarker panels was carried out in PubMed on 4th July 2024 via the following terms:

("biomarker panel*" OR "marker panel*" OR "multi biomarker*" OR "multi marker*" OR "marker combin*" OR "biomarker combin*") AND (pancrea*) AND (cancer OR carcinoma OR tumor* OR adenocarcinoma*) AND (sera OR serol* OR plasma OR blood OR "liquid biops*" OR "fluid biops*").

The literature search was restricted to articles in English and yielded 126 papers. Reviews and case reports were excluded, as were studies that did not involve research on humans, PDAC, diagnosis, or blood-based liquid biopsy. According to these criteria, a total of 57 publications were further analyzed for this review. A flow chart can be found in Fig. 2. The data extracted from the publications included study details (author, year of publication, country), biomarker details (biomarkers used, detection method, fluid type), patient cohort details (patient numbers, stage, controls), and statistical details (sensitivity, specificity, area under the curve (AUC)). If separate data for early-stage PDAC (pathological AJCC/UICC stages I and II according to the 8th edition of the staging manual) and late-stage or all-stage PDAC diagnosis were provided, only the values for early-stage PDAC were included.Fig. 2 Overview of the results from the literature search and selection of included studies

Liquid biopsy biomarkers for PDAC

Currently used tumor markers for PDAC

A commonly used serological biomarker for PDAC is carbohydrate antigen 19–9 (CA19-9), also referred to as sialyl Lewis-A, which currently represents the only FDA-approved marker. Increased levels of CA19-9 have been reported in PDAC patients compared with healthy individuals [13, 14]. The concentration of CA19-9 and its sensitivity as a diagnostic marker increase with increasing PDAC stage [15, 16], with the most pronounced increase detected between AJCC/UICC stage II and stage III. However, especially in early stages (e.g., stage I [17]), the level of CA19-9 is similar to that in various benign conditions, precancerous lesions, and other malignancies (e.g., colorectal cancer, gastric cancer, hepatocellular carcinoma), resulting in low specificity [14, 15]. With respect to its use for diagnostic purposes, it is important to consider that 6% of Caucasians and 22% of non-Caucasians who lack Lewis antigen A cannot produce CA19-9, subsequently leading to false-negative results [18]. Consequently, international guidelines do not recommend its use as a diagnostic method but rather as a longitudinal marker in patients with detectable CA19-9 at baseline [16]. Owing to the lack of robust biomarkers, various markers have been investigated as possible candidates with increased sensitivity and specificity for PDAC diagnosis. The following sections present an overview of cellular and acellular liquid biopsy-based biomarkers for PDAC diagnosis.

Cellular biomarkers

One group of biomarkers analyzed in liquid biopsy is cells that have detached from their site of origin and entered the bloodstream. These can be derived from tumor or noncancerous host cells that are part of the tumor microenvironment (TME) (e.g., immune cells, fibroblasts, and endothelial cells) [19].

Tumor cells detected in the blood are referred to as circulating tumor cells (CTCs) [9]. CTCs are highly heterogeneous even if derived from the same patient [20]. Compared with classical diagnostic biopsies (e.g., fine needle biopsy), CTCs are able to provide a more representative image of tumor heterogeneity [21–23]. However, detecting CTCs is still challenging, as approximately one CTC is detectable among more than a million other blood cells (e.g., erythrocytes, leukocytes, and platelets), and CTCs have a short half-life of only 1–2.4 h [24, 25]. In addition to the number of CTCs, their genome, transcriptome, proteome and functional properties can be analyzed [26].

With respect to PDAC, a meta-analysis of 19 studies revealed that more than half of patients (707 out of 1320 patients analyzed) had detectable CTCs in their blood [27]. These patients had lower OS and PFS rates than CTC-negative patients did, highlighting the adverse prognostic effect of CTCs in PDAC patients. However, most patients in the studies included in the meta-analysis were in advanced tumor stages (stage III and IV: 61%), with only 31% in stage II and only 8% in stage I. The low number of CTCs, particularly in early PDAC stages, may lead to false negative results and low sensitivity [12, 28]. A potential explanation for the low CTC number in PDAC could be the filtration of CTCs in the liver before they reach the peripheral blood vessels and the reduced blood flow within the cancerous pancreas [29, 30]. This limits the analysis of CTCs as possible biomarkers for early diagnosis, but with the emergence of novel, more sensitive analysis techniques (e.g., in vivo CTC capture devices [31]) and techniques that allow processing of larger volumes [32, 33], this limitation may be overcome [34]. Despite the impaired sensitivity that could arise from the different methods used or the heterogeneity of CTCs, the specificity of CTCs for PDAC diagnosis has been reported in several studies to reach > 90% [35–37].

In PDAC, cells make up only a small part of the tumor, while the largest part is the dense stroma that forms the tumor microenvironment [38]. Compared with other solid tumors, PDAC has the most pronounced desmoplastic stroma reaction, which generates a physical barrier around the tumor, thereby impairing radical resection and increasing therapy resistance [39, 40]. Although the composition and structure of the stroma varies between patients, it consists of several main components [41]. Noncellular components, including glycoproteins, fibronectins, collagens, and enzymes, form the extracellular matrix (ECM). The cellular components include endothelial, immune, and stromal cells, including pericytes, and local cancer-associated fibroblasts (CAFs). These host cells can also detach from the TME, enter the bloodstream, and be analyzed as possible liquid biopsy biomarkers for PDAC (e.g., as circulating CAFs (cCAFs)).

CAFs are key components of the TME, and they are near or in direct contact with cancer cells [38]. The three different major types of CAFs, myofibroblast CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs), are associated with distinct functions and phenotypes [42]. These functions include the production of cytokines, chemokines, metabolites, enzymes, and ECM molecules to prevent or promote tumor growth [43]. cCAFs are found in the blood of patients with various tumors, including PDAC, where they are linked to a poorer prognosis in advanced stages [44–46]. Only one study examined cCAFs in six PDAC patients and reported an association between the presence of cCAFs and poorer clinical outcomes as well as lower OS rates at metastatic stages [47]. However, to our knowledge, there are currently no studies on the role of cCAFs in the early stages of PDAC, and such studies are crucial for identifying their suitability as biomarkers for early PDAC diagnosis.

Circulating nucleic acids

Circulating tumor DNA (ctDNA) is a type of cell-free DNA (cfDNA) derived from tumor cells that can be found in the bloodstream. ctDNA can be released by cells undergoing apoptosis and necrosis or can be actively transported through the cell membrane [48]. Since only up to 1% of the cfDNA in the blood of early-stage patients originates from tumors, most detectable circulating nucleic acids are cfDNA from noncancer cells, which limits the ability to detect ctDNA [49, 50]. The amount of ctDNA in the blood varies between different tumors and increases up to 40% in advanced tumor stages [50, 51]. The half-life of ctDNA is estimated to be between 16 and 114 min, which makes isolation more challenging [52, 53]. ctDNA can be detected due to specific alterations in the tumor and can be examined for mutations, DNA integrity, gene fusion, copy number variation, or methylation status [54, 55]. The high concordance between mutations in ctDNA and those in tumor tissue makes it suitable as a biomarker that provides information about the primary tumor even if it is inaccessible [56].

Analysis of genomic aberrations in all-stages PDAC tissue revealed a panel of four genes, namely, KRAS, CDKN2A, TP53, and SMAD4, with mutation frequencies of 90%, 90%, 70%, and 55%, respectively, as the main genomic drivers of PDAC [57–61]. Interestingly, mutations in these genes can be detected in preneoplastic PanIN lesions; notably, KRAS is the first event, and subsequent alterations in CDKN2A, TP53, and SMAD4 can be detected in higher-grade PanINs [62, 63]. These mutations lead to increased proliferation, dysregulation of the cell cycle and an impaired DNA damage response [59]. As KRAS mutations are among the initiating mutations during the development of PDAC, KRAS mutations are interesting biomarkers for the early diagnosis of PDAC [64]. On the basis of the molecular profile of PDAC, several studies have used these mutations for ctDNA detection [64]. However, germline mutations in cfDNA or clonal hematopoiesis of indeterminate potential (CHIP) in noncancerous cells, especially related to KRAS (approximately 30%) [65], may lead to false-positive results and should be considered in related evaluations [55, 66, 67].

A meta-analysis of seven retrospective studies on the utility of ctDNA as a liquid biopsy biomarker revealed a sensitivity of 64% (95% CI 0.58–0.70), a specificity of 92% (95% CI 0.88–0.95), and an AUC of 0.9478 across all PDAC stages [28]. With approximately only one molecule of ctDNA in every 5 mL of plasma, the moderate sensitivity is presumably the result of minute amounts of released ctDNA, especially in the early tumor stages, when the rates of apoptosis and necrosis are lower [68, 69].

In addition to somatic cancer alterations, epigenetic traits (e.g., methylation, fragmentation) can also be examined in ctDNA. Epigenetic alterations have recently received much attention, as they may also provide tissue-specific information that helps to determine the organ in which the tumor originates. Nicholson et al. analyzed the cfDNA methylation pattern in a prospective study of 5,461 participants with suspected cancer and were able to detect different tumors with a sensitivity of 66.3% in all stages and 24.4% in stage I patients, with a specificity of 98.4% [70]. A recent publication by García-Ortiz et al. reviewed studies analyzing the ctDNA methylation status in PDAC and concluded that the use of a single epigenetic biomarker does not allow for the diagnosis of early-stage PDAC and suggested that a multimarker panel would be more efficient [71]. Moreover, fragmentomic approaches focusing on fragment size, fragment ends, and end motifs can reveal differences between ctDNA and cfDNA [72]. ctDNA from cancer patients is shorter than nontumor cfDNA, and its feautures differ between different tumor entities, which enables the identification of the tissue of origin [73, 74]. Cristiano et al. were able to detect pancreatic tumors with a sensitivity of 71% at a specificity of 95% on the basis of the cfDNA fragment size [54]. These studies underscore the promising value of cfDNA-based approaches that are independent of the presence of genomic signatures.

In addition to cfDNA, cancer cells also release cell-free RNA (cfRNA) into the circulation [75, 76]. In addition to intracellular coding messenger RNAs (mRNAs), which are required for protein synthesis, noncoding RNAs, including microRNAs (miRNAs), are potential biomarker candidates [77]. cfRNAs are highly stable, as they are typically packed in extracellular vesicles or attached to lipid or protein complexes rather than circulating freely in the bloodstream [78–82].

miRNAs are noncoding, single-strand RNAs with an average length of 22 nucleotides that are highly evolutionarily conserved among various species [83]. miRNAs can regulate their target mRNAs at the posttranscriptional level by affecting their translation and stability [84–86]. In cancer patients, altered expression of miRNAs has been reported [87]. Numerous studies examining the role of various miRNAs as LB biomarkers in PDAC have been conducted and reviewed elsewhere [57]. In a meta-analysis, Peng et al. examined miRNAs from 46 studies involving 4,326 patients with pancreatic cancer [88]. The diagnostic performance of miRNA panels, which included 4.5 miRNAs on average (range: 2–12 miRNAs), was compared to that of single miRNAs and interestingly exhibited no significant diagnostic benefit. The combined results yielded a sensitivity of 79% (0.77–0.81), a specificity of 77% (0.75–0.79), and an AUC of 0.85 (0.81–0.87). Considering only early-stage PDAC (up to stage IIA), the diagnostic value decreased slightly to a sensitivity of 79% (0.76–0.82), a specificity of 74% (0.68–0.79), and an AUC of 0.81 (0.77–0.84) [88].

Proteins

Proteins are important for communication between cancer cells and host cells in the TME [89]. Proteins can be located on the membrane surface of cells but can also be secreted in vesicles or released into the circulation [90]. A wide range of different circulating proteins, including cytokines, chemokines, carbohydrate antigens, growth factors, inflammatory factors, glycoproteins, and apolipoproteins, orchestrate numerous biological processes [91–93]. Proteins released by cancer cells can regulate the development and progression of cancer by promoting invasion and metastasis [89]. Several proteins are up- or downregulated in the blood of PDAC patients compared to that of healthy donors or benign tumor patients [94]. Hence, many circulating proteins have been analyzed as potential biomarkers for PDAC and are reviewed in more detail elsewhere [95]. However, interestingly, the sensitivity and specificity of most single proteins do not exceed those of CA19-9 [5]. A meta-analysis by Kane et al. compared 250 prospective and retrospective studies published before July 2020 on all stages of PDAC; the results revealed an AUC of 0.85 for CA19-9 alone and 0.783 for novel single biomarkers [96].

Extracellular vesicles

Extracellular vesicles (EVs) are lipid-bound and secreted particles that comprise three classes of vesicles: exosomes (30–150 nm), microvesicles (50–1000 nm), and apoptotic bodies (500–5000 nm). EVs can be released by several cell types, including neurons, epithelial cells, and fibroblasts, as well as cancer cells [97–99]. Exosomes are particularly interesting for liquid biopsy approaches because they contain many molecules, including lipids, metabolites, nucleic acids (e.g., miRNAs and mRNAs), and proteins, that are protected from degradation by the EV membrane [100]. As exosomes transfer these molecular cargoes to recipient cells through cell‒cell interactions or even over large distances, e.g., between different organs, they are important for cellular communication [101].

Exosomes influence tumor malignancy by regulating the tumor microenvironment, angiogenesis, tumor growth, invasion, and metastasis, including epithelial‒mesenchymal transition, immunomodulation, and chemoresistance [98, 102–106]. Moreover, cancer cells, including PDAC cells, secrete more exosomes than noncancerous cells [107, 108].

In a meta-analysis on the potential utility of extracellular vesicle cargo as biomarkers for PDAC, Jia et al. examined 39 studies including 2,037 PC patients [109]. Seventeen studies on EV RNAs, 16 on EV proteins, and 16 on EV biomarker panels were evaluated across all tumor stages. The most reported molecules were the EV RNAs miR-21 and miR-10b and the EV proteins GPC1 and EphQ2. A sensitivity of 84% (95% CI: 81–86%) and a specificity of 89% (95% CI: 86–91%) were obtained from the pooled values of EV RNAs and EV proteins. In contrast to analysis of the previously described biomarker types, the analysis of EVs in early PDAC stages I and II led to an increased sensitivity of 90% (95% CI: 87–93%) and specificity of 94% (95% CI: 92–95%). Interestingly, EVs as markers seem to perform at least as well and possibly even better in earlier stages (although only modestly with almost overlapping CIs) than in advanced stages [109]. One potential explanation could be that patients with advanced PDAC suffer from dysregulated EV secretion due to cancer-related effects, including cachexia and dysregulated metabolic processes. These findings indicate that exosomes and their cargo are potential biomarkers for the early diagnosis of PDAC.

Multimarker analysis

Numerous single biomarkers for the diagnosis of PDAC have been investigated, as a single marker can facilitate diagnostic assay development and implementation in routine clinical practice. However, the investigated markers have low sensitivity and specificity for diagnosis. Considering the high degree of patient diversity and tumor heterogeneity, a multimarker panel can provide complementary value and seems to perform better than single biomarkers do.

The literature search yielded 57 papers that analyzed multibiomarker panels in blood to diagnose PDAC. As some publications included two different panels, the total number of multibiomarker panels assessed was 63. Among these panels, 57 included proteins, 10 included RNA, 6 included EVs, 4 included cfDNA, 2 included metabolites, and 1 included CTCs. An overview of these studies [16, 110–165] can be found in Table 1. Table 1 Overview of multimarker studies for the (early) diagnosis of PDAC using liquid biopsy

Biomarker	SN [%]	SP [%]	AUC	Total patients [N] (female)	Stage	Control	Detection method	Fluid	Country	Reference	
Protein panels—all PC stages	
 CA19-9 + OPN + CHI3L1	93	81	N/A	52 PDAC (N/A)	II, III	43 HC	PLA	plasma	USA	Chang, 2009 [110]	
 CA19-9 + TFPI	84	90	0.94	37 PDAC (15)	I:0, II:1, III:2, IV:9, N/A:25	15 HC	ELISA	plasma	USA	Balasenthil, 2011 [111]	
 CA19-9 + ICAM-1 + OPG	78	94	0.91	173 PDAC (95)	I:4, II:37, III:20, IV:41, N/A:71	120 HC	MIA	serum	USA	Brand, 2011 [112]	
 CA19-9 + CEA + TIMP-1	71	89	0.83	173 PDAC (95)	I:4, II:37, III:20, IV:41, N/A:71	70 BD	MIA	serum	USA	Brand, 2011 [112]	
 CA19-9 + Cathepsin D + MMP-7	89	77	0.91	139 PDAC (50)	N/A	74 HC, 72 CP	MIA	serum	South Korea	Park, 2012 [113]	
 CA19-9 + AACT + THBS1 + HPT	77	90	0.92	37 PC (21)	IA:3, IB:1, IIA:6, IIB:8, III:2, IV:17	30 HC, 30 DM, 30 PC, 30 CP, 22 OJ	ELISA	serum	USA	Nie, 2014 [114]	
 CA19-9 + CEA + Cyfra 21–1	30	95	0.68	135 PC (56)	N/A	540 HC	MIA	serum	USA	Nolen, 2014 [115]	
 CA19-9 + IL-6 + IP-10 + PDGF	81	92	0.88	43 PDAC (19)	resectable:31, advanced:12	7 BD	ELISA + cytokine assay	serum	UK	Shaw, 2014 [116]	
 CA19-9 + IL-6 + IP-10 + IL-8	N/A	N/A	0.91	43 PDAC (19)	resectable:31, advanced:12	17 CP	ELISA + cytokine assay	serum	UK	Shaw, 2014 [116]	
 CA19-9 + AACT + THBS1 + SAAV peptide	100	96	0.99	26 PDAC (15)	IA:2‡, IB:1‡, IIA:3‡, IIB:7‡, IV:24‡	27 HC	ELISA + MS	serum	USA	Nie, 2014 [117]	
 CA19-9 + sLeX	76	78	N/A	109 PC (N/A)	N/A	30 BD	ELISA	plasma	USA	Tang, 2015 [118]	
 CA19-9 + APOE + ITIH3 + APOA1 + APOL1	95	94	0.99	40 PC (N/A)	N/A	34 HC	ELISA + MS	serum	China	Liu, 2017 [119]	
 CA19-9 + FVIII + fibrinogen + albumin + conjugated bilirubin + ALP	N/A	N/A	0.95	67 PDAC (36)	I-III	18 IPMN	coagulation assay	plasma	Finland	Mattila, 2018 [120]	
 CA19-9 + TSP-2	91	99	0.95	263 PDAC (140)	I-II:57, III-IV:206	230 IAR	ELISA	serum	Taiwan	Peng, 2019 [121]	
 CA19-9 + sTRA	54	95	0.86	71 PDAC (31)	I:17, II:40, III:5, IV:9	20 HC, 9 PC, 15 CP, 8 BD, 24 DM	ELISA	plasma	USA	Staal, 2019 [122]	
 CA19-9 + AGP1	89	97	0.96	52 PC (23)	N/A	34 HC	immunoturbidimetry, ELISA	serum	Sweden	Zhou, 2019 [123]	
 CA19-9 + CA125 + CEA + APOA1 + APOA2 + TTR	93	96	0.99	60 PDAC (18)	I:18, II:24, III:10, IV:8	191 HC	immunoturbidimetry, ELISA	plasma	South Korea	Kim, 2020 [124]	
 CA19-9 + CLU + C5 + KLKB1 + PPBP + IFRD1 + IGFBP2 + ICAM1 + C4BPA + PTPRJ + ECM1 + VIM + C4BPB + SERPINA5 + TTR	86	97	0.97	65 PDAC (27)	IA:1, IB:0, IIA:11, IIB:15, III:10, IV:93	59 HC, 13 BD	MS	plasma	South Korea	Kim, 2021 [125]	
 CA19-9 + S100A2 + S100A4 + CA125	N/A	N/A	0.91	120 PDAC (59)	I + II:9, III + IV:111	80 HC	ELISA	serum	Australia	Mehta, 2021 [126]	
 CA19-9 + VWF + MUC16 + THBS2 + FASLG + CEACAM5 + TLR3 + HGF + HRT + TNFRSF19 + CTSV + VEGEFA + FCRLB + ERBB4 + ANXA1 + ERBB2 + OCP + NT5E + CCN1 + TGFA	92	90	0.91	218 PDAC (N/A)	N/A	249 NC	ELISA, OLINK	serum	UK	Nené, 2023 [127]	
 CA19-9 + CEA + CA125	82	85	0.90	65 PDAC (N/A)	N/A	700 HC	ECLIA	serum	China	Cao, 2023 [128]	
 IL-7R + PLD4 + ID3	73	79	0.76	33 PDAC (N/A)	N/A	80 BD	RT-PCR	plasma	USA	Jang, 2023 [129]	
Protein panels—early PC stages (stage I-II)	
 CA19-9 + SYCN + REG1B	39	95	0.87	20 PDAC (14)	I, II	92 HC	ELISA	plasma	Canada	Makawita, 2013 [130]	
 CA19-9 + SYCN + REG1B	68	95	0.92	40 PDAC (18)	I, II	47 HC	ELISA	serum	Canada	Makawita, 2013 [130]	
 CA19-9 + CA125 + LAMC2	78	63	0.76	27 PDAC (N/A)	IA:5, IB:5, IIA:17	17 BD	ELISA	serum	Canada	Chan, 2014 [16]	
 CA19-9 + sLeX + type 1 N-acetyl-lactosamine	80	84	N/A	50 PDAC (27)	I:3, II:47	10 BD	ELISA	plasma	USA	Tang, 2016 [131]	
 CA19-9 + IGFBP2 + IGFBP3	N/A	N/A	0.90	38 PDAC (14)	I:4, II:34	65 HC	MS	plasma	Japan	Yoneyama, 2016 [132]	
 CA19-9 + LRG1 + TIMP1	67	95	0.89	39 PDAC (18)	IA:6, IB:10, resectable (no TNM data):23	82 HC	ELISA, MS	plasma	USA	Capello, 2017 [133]	
 CA19-9 + TFPI + TNC-FN III-C	75	82	0.83	98 PDAC (55)	IA:7, IB:8, II:1, IIA:40, IIB:42	61 HC	ELISA	plasma	USA	Balasenthil, 2017 [134]	
 CA19-9 + MUC5AC	75	83	0.84	63 PC (N/A)	IA:2, IB:4, IIA:18, IIB:46	35 HC, 30 BD, 43 CP	ELISA, RIA	serum	USA	Kaur, 2017 [135]	
 CA19-9 + THBS2	N/A	N/A	0.96	88 PDAC (43)	I:4, IA:2, IB:4, II:37, IIA:15, IIB:26	140 HC	ELISA	plasma	USA	Kim, 2017 [136]	
 CA19-9 + LRG1 + TTR	78	94	0.91	50 PDAC (N/A)	I:4, II:46	68 HC, 21 BD	ELISA	plasma	South Korea	Park, 2017 [137]	
 CA19-9 + MMP7	N/A	N/A	0.98	25 PDAC (N/A)	IA:2, IB:1, IIA:22	131 HC	ELISA, MIA	plasma	Italy	Resovi, 2018 [138]	
 CA19-9 + CCN2 + Col4 + FN + PLG	N/A	N/A	0.92	25 PDAC (N/A)	IA:2, IB:1, IIA:22	30 CP	ELISA, MIA	plasma	Italy	Resovi, 2018 [138]	
 CA19-9 + POSTN + CA242	92	97	0.98	38 PDAC (N/A)	IA:3, IB:5, IIA:30	37 HC	ELISA	serum	China	Dong, 2018 [139]	
 CA19-9 + MIA	N/A	N/A	0.86	96 PDAC (N/A)	IA:13, IB:18, IIA:17, IIB:48	68 CP	MIA	serum	USA	Song, 2019 [140]	
 CA19-9 + MIC-1	N/A	N/A	0.81	96 PDAC (N/A)	IA:13, IB:18, IIA:17, IIB:48	63 IPMN	MIA	serum	USA	Song, 2019 [140]	
 CA19-9 + TFF1 + TFF2 + TFF3	33	100	0.85	18 PC (N/A)	I, II	8 BD	ELISA	serum	USA	Jahan, 2019 [141]	
 CA19-9 + MUC5AC	77	89	0.89	30 PDAC (14)	N/A	34 HC, 29 BD, 35 Choledocholithiasis, 25 CP	ELISA, EIA	serum	China	Zhang, 2020 [142]	
 CA19-9 + APOA4 + CD14 + CLEC3B + GSN + HRG + ITIH3 + KLKB1 + LRG1 + SERPINF1 + SERPING1 + TIMP1	80	80	0.85	50 PDAC (N/A)	IA:3, IB:1, IIA:11, IIB:35	49 DM	ELISA, MS	plasma	USA	Peng, 2020 [143]	
 CA19-9 + LRG1 + TTR	92	88	N/A	248 PDAC (N/A)	I:20, II:228	347 HC/ gallstones/ cholecystitis	ELISA	plasma	South Korea	Choi, 2021 [144]	
 CA19-9 + LRG1 + TTR	94	91	N/A	657 PDAC (N/A)	I:39, II:618	609 HC	ELISA	plasma	South Korea	Lee, 2023 [145]	
 CA19-9 + CA125	72	80	0.81	56 PDAC (N/A)	IA:5, IB:6, IIA:9, IIB:36	53 IPMN	ECLIA	serum	USA	Song, 2021 [146]	
 EV proteins: CA19-9 + CA125 + Cathepsin D + Ferritin + sE-selectin + IGFBP3 + MIA + CA 15–3 + sFAS + TIMP1 + sNeuropilin-1 + MPO + bHCG	96	100	N/A	47 PDAC (33)	I:22, II:25	184 HC	IA	plasma	USA	Hinestrosa, 2022 [147]	
 CA19-9 + CEA + ALCM + ANG + AXL + BAG3 + BSG + CEACAM + COL18A1 + EPCAM + HA + HP + ICAM + IGFBP2 + IGFBP4 + LCN2 + LRG1 + MMP2 + MMP7 + MMP9 + MSLN + PARK7 + PPBP + PRG4 + SPRCL1 + SPP1 + TGFB1 + THBS1 + TIMP1 + TNFRSF1A + WEGFC	63	97	0.94	30 PDAC (12)	I:4: IIA:8, IIB:18	103 HC	ELISA	serum	USA	Firpo, 2023 [148]	
 CA19-9 + PIGR + vWF	N/A	N/A	0.98	28 PDAC (N/A)	IA:4, IB:5, II:2, IIB: 17	28 HC	ELISA	serum	Australia	Byeon, 2024 [149]	
DNA panels	
 BNC1 + ADAMTS1 methylation	81	85	N/A	10 PC (N/A)	I:10	26 HC	PCR, MOB	serum	USA	Yi, 2013 [150]	
 BNC1 + ADAMTS1 methylation	95	92	0.95	37 PDAC (13)	I:8, IIA:9, IIB:20	95 HC, 8 pancreatitis	PCR	plasma	USA	Eissa, 2019 [151]	
RNA panels	
 miR-642b + miR-885-5p + miR-22	91	91	0.97	11 PDAC (6)	II	11 HC, 11 IAR	qRT-PCR	plasma	USA	Ganepola, 2014 [152]	
 EV miRNA: miR-93-5p + miR-339-3p + miR-425-5p + miR-425-3p	80	95	0.89	15 PDAC (2)	I:3, II:2, III:3, IV:7	19 C	qRT-PCR	plasma	USA	Makler, 2023 [153]	
 miR-28-3p, miR-143-3p, and miR-151a-3p	N/A	N/A	0.81	14 PDAC (N/A)	I:8, II:6	107 C	qRT-PCR	plasma	China	Yang, 2024 [154]	
multi-omics panels—all PC stages	
 CD44v6 + Tspan8 + EpCAM + MET + CD104 + miR-1246 + miR-4644 + miR-3976 + miR-4306	100	80	N/A	131 PC (76)	N/A	30 HC, 20 BD, 25 C, 12 non-PC	qRT-PCR, flow cytometry	serum	Germany	Madhavan, 2015 [155]	
 CA19-9 + MIC-1 + miR-21	88	99	0.97	82 PC (35)	I:1, II:7, III:51, IV:23	88 HC	RT-PCR, ELISA	plasma	China	Yuan, 2016 [156]	
 CA19-9 + MIC-1 + miR-25	84	100	0.97	82 PC (35)	I:1, II:7, III:51, IV:23	88 HC	RT-PCR, ELISA	plasma	China	Yuan, 2016 [156]	
 CA19-9 + THBS2 + cfDNA quantification	87	92	0.94	52 PDAC (26)	I:14, II:17, III:21	15 IPMN, 32 pancreatitis	ELISA, Qubit	plasma	Germany	Berger, 2019 [157]	
 CA19-9 + EV: miR200b + miR200c	92	100	0.97	56 PDAC (20)	IIA:4, IIB:14, III:22, IV:24	22 HC + 11 CP	PCR, western blot	serum	Germany	Reese, 2020 [158]	
 CA19-9 + CTC quantification	91	91	0.95	80 PDAC (29)	I + II:40, III + IV:40	34 HC, 32 AP, 22 BD	NE-imFISH, ECLIA	whole blood, plasma	China	Chen, 2022 [159]	
Multi-omics panel—early PC stages (stage I-II)	
 CA19-9 + CEA + HGF + OPN + ctDNA: KRAS mutation	64	100	N/A	221 PDAC (100)	I:29, II:192	182 HC	PCR, MIA	plasma	multi-center	Cohen, 2017 [160]	
 CA19-9 + LRG1 + TIMP1 + acetylspermidine + diacetylspermine + indole-derivative + two lysophosphatidylcholines	90	88	0.92	39 PDAC (18)	IA:6, IB:10, resectable (no staging data):23	82 HC	ELISA, MS	plasma	USA	Fahrmann, 2019 [161]	
 CA19-9 + cf miRNA: miR30c-5p, miR340-5p, miR335-5p, miR23b-3p, miR142-3p + EV miRNA: miR145-5p, miR200b-3p, miR429, miR1260b, miR145-3p, miR216b-5p, miR200a-3p, miR217-5p	84	99	0.99	91 PDAC (N/A)	I:36, II:55	67 HC	qRT-PCR, ELISA	plasma + serum	USA, Japan, South Korea	Nakamura, 2022 [162]	
 CA19-9 + proline + creatine + palmitic acid	86	82	0.95	22 PDAC (11)	IA:2, IB:6, IIA:2, IIB:12	27 HC	MS	serum	China	Zhao, 2023 [163]	
 CA19-9 + hsa_circ_0060733 + hsa_circ_0006117 + hsa_circ_0064288 + hsa_circ_0007895 + hsa_circ_0007367	77	95	0.94	63 PDAC (N/A)	I, II	46 HC	qRT-PCR	plasma	USA	Xu, 2023 [164]	
 EV: CD63 + GPC-1 + HER2 + snRNA U6 + GPC-1 mRNA + miR-10b	N/A	N/A	0.93	15 PDAC (8)	IA:1, IB:9, IIA:3, IIB: 2	15 HC	Co-PAR	plasma	China	He, 2024 [165]	
Abbreviations: AC Acute pancreatitis, AUC Area under the curve, BD Benign disease, C Control (undefined), Co-PAR Codetection platform of Proteins and RNAs, CP Chronic pancreatitis, ECLIA electrochemiluminescence-based immunoassay, EIA Enzyme immunoassay, ELISA Enzyme-linked immunosorbent assay, DM Diabetes mellitus, HC Healthy control, IA Immunoassay, IAR Individual at risk, IPMN Intraductal papillary mucinous neoplasm, MIA Magnetic immunoassay, MS Mass spectrometry, N/A Not available, PC Pancreatic cancer, PCR Polymerase chain reaction, PDAC Pancreatic adenocarcinoma, SN Sensitivity, SP Specificity. ‡ As only TNM stage data were present in the original study, staging was assessed according to the 8th edition of the UICC staging manual

Many publications started by analyzing single biomarkers and later combined them with one or more other biomarkers. The addition of biomarkers led to increased sensitivity and specificity and improved AUC values in these studies. For example, Capello et al. calculated an AUC of 0.730 for TIMP1, 0.832 for LRG2, and 0.821 for CA19-9 to distinguish early-stage PDAC patients from healthy controls [133]. The combination of all three protein markers increased the AUC to 0.887, and adding 5 metabolites to the protein panel further increased the AUC to 0.924 [161]. This observation was quantified in the above-mentioned meta-analysis by Kane et al. [96]. The pooled AUC for studies with single biomarkers was 0.803, which was significantly lower than the multibiomarker panel AUC of 0.898. However, this analysis was performed on all stages of PDAC and did not focus particularly on the early stages.

The investigated biomarkers were combined with CA19-9 analysis in 55 of the 63 studies, and only 8 studies did not include CA19-9 in their panel [129, 150–155, 165]. Adding CA19-9 to other biomarkers improved the diagnostic power. For example, Dong et al. examined the proteins POSTN and CA242 in early-stage PDAC patients versus healthy controls and reported an AUC of 0.92 for their combination [139]. The addition of CA19-9 to the panel increased the AUC to 0.98.

Most biomarker panels included only protein markers (46 out of 63 studies) that were analyzed directly from the blood or isolated from EVs. In the studies on early-stage PDAC, the AUCs ranged from 0.76–0.98 (Fig. 3). The protein panels consisted of two proteins in 7 studies, three proteins in 11 studies, and four or more proteins in 5 studies, although the number of proteins did not appear to directly correlate with the reported AUC. The biomarker panels included numerous different proteins, whereas only some proteins, including CA19-9, CEA, and MUC5AC, were found in several panels. Hinestrosa et al. isolated EVs from the blood of early PDAC patients and healthy controls and analyzed a panel of 13 proteins within EVs, resulting in a sensitivity of 95.7% and specificity of 99.5% [147].Fig. 3 Distribution of the AUC values of multibiomarker panels in identifying stage I and II PDAC patients. The AUC values derived from Table 1 for the multibiomarker panels for early-stage PDAC are plotted. The figure includes multimarker panels consisting of combinations of proteins (20 studies), DNA (1 study), RNA (2 studies) or multiomic markers (5 studies)

Only five studies focused on other types of biomarkers, namely, cfDNA [150, 151] or RNA [152–154]. Eissa et al. analyzed the cfDNA methylation pattern of the BNC1 and ADAMTS1 genes and reported the ability to distinguish early-stage PDAC patients from mixed controls, with an AUC of 0.95 [150, 151]. Ganepola et al. compared the miRNAs miR-642b, miR-885-5p, and miR-22 between stage II PDAC patients and healthy controls as well as high-risk patients, resulting in an AUC of 0.97 [152]. A prospective study analyzing the 2’-O-methylated miRNAs miR-28-3p, miR-143-3p, and miR-151a-3p in 135 individuals was performed by Yang et al. The panel identified 20 out of 28 early-stage PDAC patients, resulting in an AUC of 0.81 [154].

Furthermore, several studies have investigated multiomic panels by combining analyses of CTCs, cfDNA, metabolites, or miRNAs with proteins [155–165]. The only reviewed study that included CTCs for PDAC diagnosis was performed by Chen et al. [159]. The authors isolated and quantified CTCs from whole blood and added CA19-9 analysis to distinguish all-stage PDAC patients from mixed controls with an AUC of 0.95. Two studies analyzed cfDNA in combination with different proteins: Cohen et al. focused on four proteins (CA19-9, CEA, HGF, OPN) and KRAS mutations in cfDNA, distinguishing early-stage PDAC patients from healthy controls with a sensitivity of 64% and a specificity of 99.5% [160]. In a different cfDNA analysis approach, Berger et al. quantified ctDNA and analyzed CA19-9 and THBS2 to differentiate between all-stage PDAC, IPMN and pancreatitis, with an AUC of 0.94 [157]. Metabolites were included in the studies of Fahrmann et al. and Zhao et al. to distinguish early-stage PDAC patients from healthy controls. The multibiomarker panel of Fahrmann et al. consisted of five metabolites (acetylspermidine, diacetylspermine, an indole-derivative, and two lysophosphatidylcholines) and three proteins (CA19-9, LRG1, and TIMP1), resulting in an AUC of 0.924 [161]. Zhao et al. combined three metabolites (proline, creatine, and palmitic acid) with CA19-9, and this panel had an AUC of 0.949 [163]. Seven studies involved combined analysis of proteins with cell-free RNAs or miRNAs isolated from EVs [155, 156, 158, 162, 164, 165]. Nakamura et al. combined CA19-9 with 5 cell-free miRNAs (miR30c-5p, miR340-5p, miR335-5p, miR23b-3p, and miR142-3p) and 8 EV-derived miRNAs (miR145-5p, miR200b-3p, miR429, miR1260b, miR145-3p, miR216b-5p, miR200a-3p, and miR217-5p) [162]. This biomarker panel had an AUC of 0.99 for distinguishing early-stage PDAC patients from healthy controls, indicating that it was the most precise diagnostic panel among all reviewed studies on early-stage PDAC. However, there were some limitations to this study, such as the modest sample size (n = 91) and the lack of age-matched control groups, which need to be addressed before the biomarker panel can be applied in the clinic.

The analyzed biomarkers were tested on early-stage PDAC patient samples in 34 of the 63 studies and had AUCs in the range of 0.76–0.99 (Fig. 3). The protein panels had the lowest mean AUC of 0.89, and the range of AUC values was the widest. The multiomic panels had the highest mean AUC of 0.95, with a small range from 0.92–0.99, indicating that combining different omic biomarkers yields greater statistical power. However, compared with single markers or panels with only one type of marker (e.g., protein), multimarker panels, particularly multiomic panels, involve more elaborate integrative assays with potentially increased development time and greater complexity.

These studies indicate that several biomarkers perform well in detecting early-stage PDAC. However, for these markers to be used for the screening of risk groups, the sensitivity and specificity need to be increased to minimize the number of false positive and negative diagnoses. In particular, high sensitivity is difficult to reach, as PDAC shares numerous biomarkers and mutations (e.g., RAS mutations) with other diseases (e.g., colorectal cancer), benign diseases of the pancreas (e.g., pancreatitis) or its precancerous lesions (e.g., IPMN), and these other diseases have higher prevalence in the general population than PDAC [166, 167]. Diseased controls (e.g., those with precancerous conditions, pancreatitis, and pancreatic cysts) and individuals at risk for developing PDAC should be included in studies to minimize false-positive rates and gain further knowledge of the molecular tumorigenesis of PDAC. On the basis of these assumptions, screening for PDAC in the general population could be implemented in pancancer screening efforts rather than as a specific test for PDAC. A panel of multiple markers could be used to screen for several cancer types at the same time and therefore be used on a broader group of individuals. Two multimarker panel-base tests, CancerSEEK [168] and Galleri (GRAIL) [169–172], were developed to detect the early stages of multiple tumors, including PDAC. The CancerSEEK multimarker panel includes ctDNA and eight proteins (CA-125, CEA, CA19-9, PRL, HGF, OPN, MPO, and TIMP-1) to detect ovarian, liver, stomach, pancreatic, esophageal, colorectal, lung and breast tumors. Currently, the CancerSEEK test is only used in clinical trials (NCT04213326). The Galleri test by GRAIL, which is already commercially available, analyzes the whole-genome methylation of cfDNA to detect signals of more than 50 cancer types. In an independent validation set of 4,077 individuals, the test was able to identify 35 of 41 patients with early-stage pancreatic cancer, resulting in a sensitivity of approximately 60% at 99.5% specificity [171]. Moreover, in another prospective study of 6,662 participants, the Galleri test detected a suspicious positive cancer signal in 92 cases [172]. After 12 months of follow-up, 35 of these 92 participants (38%) were confirmed to have a true positive cancer diagnosis, and 6,235 of the 6,549 (95.5%) participants without a cancer signal had true negative results, highlighting the feasibility of multicancer early detection (MCED) testing. Moreover, for the first time, this study assessed the subsequent diagnostic pathways and time to diagnostic resolution [172]. Notably, these studies by Schrag et al., are highly important for emphasizing the clinical utility of screening approaches (e.g., MCED tests), even in nonrisk groups.

Another study on the methylation of cfDNA, the THUNDER study, yielded high sensitivity for advanced stages but only approximately 35% sensitivity for stages I and II, with 98.9% specificity for detecting pancreatic tumors [173]. Although the specificity of the tests is sufficient, the sensitivity for early-stage diagnosis is lower than that of the PDAC-specific panels outlined in this review and therefore indicates that high-risk groups may benefit from a PDAC-specific screening approach. Moreover, the number of false-negative results leads to high costs for further diagnosis and insecurities for tested individuals. However, for some cancer types, the sensitivity reached relatively high values (e.g., 100% (CancerSEEK), 100% (Galleri), and 75% (THUNDER) for diagnosing stage I liver cancer). With respect to the diagnosis of advanced stages, the sensitivity was 80% to 100% for several cancer types in all tests. Further investigations on early-stage cancers are necessary to establish a reliable multicancer test, which would greatly improve the diagnosis of cancer.

In many of the reported PDAC studies in this review, several limitations affected the results of the analyses. Only 34 of the 63 studies assessed the analyzed biomarkers in early-stage PDAC patient samples. Notably, surgery is most efficient treatment in the early stages of PDAC and can significantly improve the OS of patients [5, 174, 175]. Thus, studies focusing on samples of early-stage patients are urgently needed to find suitable biomarkers for early diagnosis. Moreover, many studies analyzing single or multiple biomarkers had small samples sizes, resulting in low statistical power. Considering the high heterogeneity of patients and tumors, large cohorts (optimally from multiple centers) are needed to reliably assess biomarkers. Another limitation of most studies is the retrospective study design. Although many samples were collected prospectively, the analysis was performed retrospectively on chosen samples. Only three biomarker panels were tested in a prospective study [115, 129, 176], yielding a higher level of medical evidence. Another important aspect for future studies is the standardization of preanalytical factors as well as methods used for detection. Multicenter evaluation of CTCs, DNAs, and miRNAs in standardized blood samples revealed significant differences between the technologies used at different centers [177–179], which prevents the comparison of results and thereby limits the development of novel diagnostic assays. Therefore, it is necessary to use standardized protocols for the handling of samples and the performance of assays to improve the quality of studies. Several international liquid biopsy consortia and societies, including the European Liquid Biopsy Society (ELBS) and the International Liquid Biopsy Standardization Alliance (ILSA), are currently collaborating on this task. The establishment of reference and uniform cutoff values for promising biomarkers is important for performing randomized prospective studies to obtain more robust medical evidence. These prospective studies must be hypothesis-driven and have defined enrollment criteria to avoid the risk of missing many specific features related to the complex clinical condition of pancreatic cancer to address unmet needs. Moreover, after these studies have been completed, it is highly important to systematically review or conduct a meta-analysis of the available studies to select the best features and guide further diagnostic assay development.

Conclusion and perspectives

This review of studies on using multimarker panels in blood samples to diagnose PDAC revealed that the use of panels of multiple biomarkers compared with single biomarkers improved the diagnostic power. Most studies have been performed on protein panels, whereas only a few have analyzed other biomarker types or even multiomic panels. Although many biomarkers had low diagnostic power alone, the combination of these biomarkers with CA19-9 increased the diagnostic power; thus, CA19-9 is part of many multibiomarker panels. For future studies, it is crucial to conduct prospective studies with standardized methods and to use samples of patients in the early stages to enable the development of a biomarker panel for early-stage PDAC diagnosis, allowing early therapeutic intervention. Owing to the low number of early-stage PDAC patients, collaborative efforts in a multicenter setting are needed. Currently, 361 ongoing studies on early-stage diagnosis of pancreatic cancer are listed at clinicaltrials.gov, illustrating the unmet need for reliable early detection methods. More than 40% of these ongoing studies (152 studies) include liquid biopsy-based diagnostics, and four of these liquid biopsy-based studies are MCED tests that utilize DNA methylation or multiomic panels. One of these recent liquid biopsy-based studies was initiated by the EU-funded PANCAID consortium [180]. Researchers in the PANCAID consortium have committed their research toward finding novel minimally invasive multimarker panels for early PDAC detection. Findings related to the early-stage detection of primary disease may also apply to the early diagnosis of minimal residual disease in cancer patients who have undergone treatment with curative intent after diagnosis [181, 182]. The European Consortium GUIDE.MRD is currently tackling this ambitious task for the detection of ctDNA in patients with pancreatic, colorectal, and lung cancers [183].

Abbreviations

AC Acute pancreatitis

apCAFs Antigen-presenting CAFs

AUC Area under the curve

BD Benign disease

CA19-9 Carbohydrate antigen 19–9

CAF Cancer-associated fibroblast

cCAF Circulating CAF

cfDNA Cell-free DNA

cfRNA Cell-free RNA

CHIP Clonal hematopoiesis of indeterminate potential

CP Chronic pancreatitis

CTC Circulating tumor cell

ctDNA Circulating tumor DNA

DM Diabetes mellitus

ECLIA Electrochemiluminescent-based immunoassays

EIA Enzyme immunoassay

ELISA Enzyme-linked immunosorbent assay

EV Extracellular vesicle

HC Healthy control

IA Immunoassay

IAR Individuals at risk

iCAF Inflammatory CAF

IPMN Intraductal papillary mucinous neoplasm

LB Liquid biopsy

MCED Multi-cancer early detection

MCN Mucinous cystic neoplasm

MIA Magnetic immunoassay

miRNA MicroRNAs

MOB Methylation on beads

mRNA Messenger RNA

MS Mass spectrometry

myCAF Myofibroblast CAF

OS Overall survival

PanIN Pancreatic intraepithelial neoplasm

PC Pancreatic cyst

PCR Polymerase chain reaction

PDAC Pancreatic ductal adenocarcinoma

PFS Progression-free survival

PLA Proximity ligation assay

RIA Radioimmunoassay

SN Sensitivity

SP Specificity

TME Tumor microenvironment

Acknowledgements

This work was funded by the European Union. Views and opinions expressed are those of the authors only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authorities can be held responsible for them.

We would like to thank Sian Haynes-Ryterski for proofreading the manuscript.

Authors’ contributions

K.-L.R. reviewed the literature and wrote the original draft of the manuscript. K.P. and D.J.S. reviewed the literature and critically revised the original draft. All authors have read and agreed to the published version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. K.P. received grant/research support from the EU/IHI GUIDE.MRD (No. 101112066), EU Horizon PANCAID (No. 101096309) and ERC Grant INJURMET (No. 834974). The position of K.-L.R. and in part the position of D.J.S. were funded through the PANCAID project within the EU Horizon Mission Cancer Program (No. 101096309)).

K.P. and D.J.S. received funding from the Fleur Hiege Center for Skin Cancer Research (funded by the Hiege Stiftung) outside of this work.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

K.P. received honoraria outside of this work from NRich, BMS, Agena, Menarini, Novartis, Sanofi, Illumina, Abcam, MSD, Eppendorf, and Hummingbird. K.-L.R. and D.J.S. declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Liou GY Byrd CJ Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need Cancers (Basel) 2023 15 9 2446 10.3390/cancers15092446 37173913
Liou GY, Byrd CJ. Diagnostic bioliquid markers for pancreatic cancer: what we have vs. what we need. Cancers (Basel). 2023;15(9):2446.37173913 10.3390/cancers15092446
2. Maisonneuve P Lowenfels AB Risk factors for pancreatic cancer: a summary review of meta-analytical studies Int J Epidemiol 2014 44 1 186 198 10.1093/ije/dyu240 25502106
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2014;44(1):186–98.25502106 10.1093/ije/dyu240
3. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 2021 71 3 209 49 10.3322/caac.21660 33538338
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.33538338 10.3322/caac.21660
4. Siegel RL Miller KD Fuchs HE Jemal A Cancer Statistics, 2021 CA Cancer J Clin 2021 71 1 7 33 10.3322/caac.21654 33433946
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.33433946 10.3322/caac.21654
5. Al-Shaheri FN Alhamdani MSS Bauer AS Giese N Büchler MW Hackert T Blood biomarkers for differential diagnosis and early detection of pancreatic cancer Cancer Treat Rev 2021 96 102193 10.1016/j.ctrv.2021.102193 33865174
Al-Shaheri FN, Alhamdani MSS, Bauer AS, Giese N, Büchler MW, Hackert T, et al. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Cancer Treat Rev. 2021;96: 102193.33865174 10.1016/j.ctrv.2021.102193
6. Michl P Löhr M Neoptolemos JP Capurso G Rebours V Malats N UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better United European Gastroenterol J. 2021 9 7 860 71 10.1002/ueg2.12123 34431604
Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, et al. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J. 2021;9(7):860–71.34431604 10.1002/ueg2.12123
7. Neoptolemos JP Stocken DD Friess H Bassi C Dunn JA Hickey H A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 2004 350 12 1200 1210 10.1056/NEJMoa032295 15028824
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.15028824 10.1056/NEJMoa032295
8. Chhoda A Lu L Clerkin BM Risch H Farrell JJ Current Approaches to Pancreatic Cancer Screening Am J Pathol 2019 189 1 22 35 10.1016/j.ajpath.2018.09.013 30558719
Chhoda A, Lu L, Clerkin BM, Risch H, Farrell JJ. Current approaches to pancreatic cancer screening. Am J Pathol. 2019;189(1):22–35.30558719 10.1016/j.ajpath.2018.09.013
9. Pantel K Alix-Panabières C Circulating tumour cells in cancer patients: challenges and perspectives Trends Mol Med 2010 16 9 398 406 10.1016/j.molmed.2010.07.001 20667783
Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406.20667783 10.1016/j.molmed.2010.07.001
10. Kamyabi N Bernard V Maitra A Liquid biopsies in pancreatic cancer Expert Rev Anticancer Ther 2019 19 10 869 878 10.1080/14737140.2019.1670063 31533487
Kamyabi N, Bernard V, Maitra A. Liquid biopsies in pancreatic cancer. Expert Rev Anticancer Ther. 2019;19(10):869–78.31533487 10.1080/14737140.2019.1670063
11. Lianidou E Pantel K Liquid biopsies Genes Chromosomes Cancer 2019 58 4 219 232 10.1002/gcc.22695 30382599
Lianidou E, Pantel K. Liquid biopsies. Genes Chromosomes Cancer. 2019;58(4):219–32.30382599 10.1002/gcc.22695
12. Alix-Panabières C Pantel K Liquid Biopsy: From Discovery to Clinical Application Cancer Discov 2021 11 4 858 873 10.1158/2159-8290.CD-20-1311 33811121
Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858–73.33811121 10.1158/2159-8290.CD-20-1311
13. Del Villano BC Brennan S Brock P Bucher C Liu V McClure M Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9 Clin Chem 1983 29 3 549 552 10.1093/clinchem/29.3.549 6825270
Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9. Clin Chem. 1983;29(3):549–52.6825270 10.1093/clinchem/29.3.549
14. Lee T Teng TZJ Shelat VG Carbohydrate antigen 19–9 - tumor marker: Past, present, and future World J Gastrointest Surg 2020 12 12 468 490 10.4240/wjgs.v12.i12.468 33437400
Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19–9 - tumor marker: Past, present, and future. World J Gastrointest Surg. 2020;12(12):468–90.33437400 10.4240/wjgs.v12.i12.468
15. Goonetilleke KS Siriwardena AK Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol 2007 33 3 266 270 10.1016/j.ejso.2006.10.004 17097848
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.17097848 10.1016/j.ejso.2006.10.004
16. Chan A Prassas I Dimitromanolakis A Brand RE Serra S Diamandis EP Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer Clin Cancer Res. 2014 20 22 5787 95 10.1158/1078-0432.CCR-14-0289 25239611
Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 2014;20(22):5787–95.25239611 10.1158/1078-0432.CCR-14-0289
17. Qu D Johnson J Chandrakesan P Weygant N May R Aiello N Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells PLoS ONE 2015 10 2 e0118933 10.1371/journal.pone.0118933 25723399
Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, et al. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS ONE. 2015;10(2): e0118933.25723399 10.1371/journal.pone.0118933
18. Scarà S Bottoni P Scatena R CA 19–9: Biochemical and Clinical Aspects Adv Exp Med Biol 2015 867 247 260 10.1007/978-94-017-7215-0_15 26530370
Scarà S, Bottoni P, Scatena R. CA 19–9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–60.26530370 10.1007/978-94-017-7215-0_15
19. Alix-Panabières C Pantel K Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy Cancer Discov 2016 6 5 479 491 10.1158/2159-8290.CD-15-1483 26969689
Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016;6(5):479–91.26969689 10.1158/2159-8290.CD-15-1483
20. Alix-Panabières C Pantel K Circulating Tumor Cells: Liquid Biopsy of Cancer Clin Chem 2013 59 1 110 118 10.1373/clinchem.2012.194258 23014601
Alix-Panabières C, Pantel K. Circulating Tumor Cells: Liquid Biopsy of Cancer. Clin Chem. 2013;59(1):110–8.23014601 10.1373/clinchem.2012.194258
21. Nikanjam M Kato S Kurzrock R Liquid biopsy: current technology and clinical applications J Hematol Oncol 2022 15 1 131 10.1186/s13045-022-01351-y 36096847
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131.36096847 10.1186/s13045-022-01351-y
22. Gerlinger M Rowan AJ Horswell S Math M Larkin J Endesfelder D Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 2012 366 10 883 892 10.1056/NEJMoa1113205 22397650
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.22397650 10.1056/NEJMoa1113205
23. Bingham C Fernandez SV Fittipaldi P Dempsey PW Ruth KJ Cristofanilli M Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients Breast Cancer Res Treat 2017 163 2 219 230 10.1007/s10549-017-4176-x 28271309
Bingham C, Fernandez SV, Fittipaldi P, Dempsey PW, Ruth KJ, Cristofanilli M, et al. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res Treat. 2017;163(2):219–30.28271309 10.1007/s10549-017-4176-x
24. Barradas AM Terstappen LW Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis Cancers (Basel) 2013 5 4 1619 1642 10.3390/cancers5041619 24305653
Barradas AM, Terstappen LW. Towards the biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel). 2013;5(4):1619–42.24305653 10.3390/cancers5041619
25. Meng S Tripathy D Frenkel EP Shete S Naftalis EZ Huth JF Circulating tumor cells in patients with breast cancer dormancy Clin Cancer Res 2004 10 24 8152 8162 10.1158/1078-0432.CCR-04-1110 15623589
Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10(24):8152–62.15623589 10.1158/1078-0432.CCR-04-1110
26. Smit DJ, Schneegans S, Pantel K. Clinical applications of circulating tumor cells in patients with solid tumors. Clin Exp Metastasis. 2024. 10.1007/s10585-024-10267-5.
27. Wang Y Yu X Hartmann D Zhou J Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis HPB (Oxford) 2020 22 5 660 669 10.1016/j.hpb.2019.11.003 31786054
Wang Y, Yu X, Hartmann D, Zhou J. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis. HPB (Oxford). 2020;22(5):660–9.31786054 10.1016/j.hpb.2019.11.003
28. Zhu Y Zhang H Chen N Hao J Jin H Ma X Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis Medicine 2020 99 3 e18581 10.1097/MD.0000000000018581 32011436
Zhu Y, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: a systematic review and meta-analysis. Medicine. 2020;99(3): e18581.32011436 10.1097/MD.0000000000018581
29. Komar G Kauhanen S Liukko K Seppänen M Kajander S Ovaska J Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness Clin Cancer Res 2009 15 17 5511 5517 10.1158/1078-0432.CCR-09-0414 19706808
Komar G, Kauhanen S, Liukko K, Seppänen M, Kajander S, Ovaska J, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15(17):5511–7.19706808 10.1158/1078-0432.CCR-09-0414
30. Catenacci DV Chapman CG Xu P Koons A Konda VJ Siddiqui UD Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound Gastroenterology 2015 149 7 1794 803.e4 10.1053/j.gastro.2015.08.050 26341722
Catenacci DV, Chapman CG, Xu P, Koons A, Konda VJ, Siddiqui UD, et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology. 2015;149(7):1794–803.e4.26341722 10.1053/j.gastro.2015.08.050
31. Markou A Lazaridou M Paraskevopoulos P Chen S Świerczewska M Budna J Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients Clin Chem 2018 64 2 297 306 10.1373/clinchem.2017.275503 29122836
Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, et al. Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high-risk prostate cancer patients. Clin Chem. 2018;64(2):297–306.29122836 10.1373/clinchem.2017.275503
32. Fehm TN Meier-Stiegen F Driemel C Jäger B Reinhardt F Naskou J Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting Cytometry A 2018 93 12 1213 1219 10.1002/cyto.a.23669 30551262
Fehm TN, Meier-Stiegen F, Driemel C, Jäger B, Reinhardt F, Naskou J, et al. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A. 2018;93(12):1213–9.30551262 10.1002/cyto.a.23669
33. Stoecklein NH Fluegen G Guglielmi R Neves RPL Hackert T Birgin E Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis Mol Cancer 2023 22 1 181 10.1186/s12943-023-01880-1 37957606
Stoecklein NH, Fluegen G, Guglielmi R, Neves RPL, Hackert T, Birgin E, et al. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Mol Cancer. 2023;22(1):181.37957606 10.1186/s12943-023-01880-1
34. Keller L Pantel K Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells Nat Rev Cancer 2019 19 10 553 567 10.1038/s41568-019-0180-2 31455893
Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19(10):553–67.31455893 10.1038/s41568-019-0180-2
35. Khoja L Backen A Sloane R Menasce L Ryder D Krebs M A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker Br J Cancer 2012 106 3 508 516 10.1038/bjc.2011.545 22187035
Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106(3):508–16.22187035 10.1038/bjc.2011.545
36. Rhim AD Mirek ET Aiello NM Maitra A Bailey JM McAllister F EMT and dissemination precede pancreatic tumor formation Cell 2012 148 1–2 349 361 10.1016/j.cell.2011.11.025 22265420
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.22265420 10.1016/j.cell.2011.11.025
37. Ankeny JS Court CM Hou S Li Q Song M Wu D Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer Br J Cancer 2016 114 12 1367 1375 10.1038/bjc.2016.121 27300108
Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016;114(12):1367–75.27300108 10.1038/bjc.2016.121
38. Kuznetsova A Popova O Panchenkov D Dyuzheva T Ivanov A Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies Clin Exp Med 2023 23 3 619 643 10.1007/s10238-022-00886-1 36085429
Kuznetsova A, Popova O, Panchenkov D, Dyuzheva T, Ivanov A. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Clin Exp Med. 2023;23(3):619–43.36085429 10.1007/s10238-022-00886-1
39. Thomas D Radhakrishnan P Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis Mol Cancer 2019 18 1 14 10.1186/s12943-018-0927-5 30665410
Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18(1):14.30665410 10.1186/s12943-018-0927-5
40. Jacobetz MA Chan DS Neesse A Bapiro TE Cook N Frese KK Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer Gut 2013 62 1 112 120 10.1136/gutjnl-2012-302529 22466618
Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20.22466618 10.1136/gutjnl-2012-302529
41. Arneth B Tumor Microenvironment Medicina (Kaunas). 2019 56 1 15 10.3390/medicina56010015 31906017
Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019;56(1):15.31906017 10.3390/medicina56010015
42. Götze J Nitschke C Uzunoglu FG Pantel K Sinn M Wikman H Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications Front Cell Dev Biol 2022 10 918795 10.3389/fcell.2022.918795 35712663
Götze J, Nitschke C, Uzunoglu FG, Pantel K, Sinn M, Wikman H. Tumor-stroma interaction in PDAC as a new approach for liquid biopsy and its potential clinical implications. Front Cell Dev Biol. 2022;10: 918795.35712663 10.3389/fcell.2022.918795
43. Kalluri R The biology and function of fibroblasts in cancer Nat Rev Cancer 2016 16 9 582 598 10.1038/nrc.2016.73 27550820
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98.27550820 10.1038/nrc.2016.73
44. Ao Z Shah SH Machlin LM Parajuli R Miller PC Rawal S Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer Cancer Res 2015 75 22 4681 4687 10.1158/0008-5472.CAN-15-1633 26471358
Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, et al. Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer. Cancer Res. 2015;75(22):4681–7.26471358 10.1158/0008-5472.CAN-15-1633
45. Jones ML Siddiqui J Pienta KJ Getzenberg RH Circulating fibroblast-like cells in men with metastatic prostate cancer Prostate 2013 73 2 176 181 10.1002/pros.22553 22718300
Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH. Circulating fibroblast-like cells in men with metastatic prostate cancer. Prostate. 2013;73(2):176–81.22718300 10.1002/pros.22553
46. Richardson AM Havel LS Koyen AE Konen JM Shupe J Wiles WG IV Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion Clin Cancer Res 2018 24 2 420 432 10.1158/1078-0432.CCR-17-1776 29208669
Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG IV, et al. Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res. 2018;24(2):420–32.29208669 10.1158/1078-0432.CCR-17-1776
47. Ortiz-Otero N Marshall JR Lash B King MR Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients BMC Cancer 2020 20 1 873 10.1186/s12885-020-07376-1 32917154
Ortiz-Otero N, Marshall JR, Lash B, King MR. Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients. BMC Cancer. 2020;20(1):873.32917154 10.1186/s12885-020-07376-1
48. Schwarzenbach H Hoon DS Pantel K Cell-free nucleic acids as biomarkers in cancer patients Nat Rev Cancer 2011 11 6 426 437 10.1038/nrc3066 21562580
Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.21562580 10.1038/nrc3066
49. Jaworski JJ Morgan RD Sivakumar S Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer Cancers (Basel). 2020 12 12 3704 10.3390/cancers12123704 33317202
Jaworski JJ, Morgan RD, Sivakumar S. Circulating cell-free tumour DNA for early detection of pancreatic cancer. Cancers (Basel). 2020;12(12):3704.33317202 10.3390/cancers12123704
50. Bettegowda C Sausen M Leary RJ Kinde I Wang Y Agrawal N Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Transl Med. 2014 6 224 224ra24 10.1126/scitranslmed.3007094 24553385
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.24553385 10.1126/scitranslmed.3007094
51. Newman AM Bratman SV To J Wynne JF Eclov NC Modlin LA An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Nat Med 2014 20 5 548 554 10.1038/nm.3519 24705333
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54.24705333 10.1038/nm.3519
52. Diehl F Schmidt K Choti MA Romans K Goodman S Li M Circulating mutant DNA to assess tumor dynamics Nat Med 2008 14 9 985 990 10.1038/nm.1789 18670422
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.18670422 10.1038/nm.1789
53. Lo YMD Zhang J Leung TN Lau TK Chang AMZ Hjelm NM Rapid Clearance of Fetal DNA from Maternal Plasma Am J Hum Genet 1999 64 1 218 224 10.1086/302205 9915961
Lo YMD, Zhang J, Leung TN, Lau TK, Chang AMZ, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218–24.9915961 10.1086/302205
54. Cristiano S Leal A Phallen J Fiksel J Adleff V Bruhm DC Genome-wide cell-free DNA fragmentation in patients with cancer Nature 2019 570 7761 385 389 10.1038/s41586-019-1272-6 31142840
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–9.31142840 10.1038/s41586-019-1272-6
55. Keller L Belloum Y Wikman H Pantel K Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond Br J Cancer 2021 124 2 345 358 10.1038/s41416-020-01047-5 32968207
Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345–58.32968207 10.1038/s41416-020-01047-5
56. Zill OA Greene C Sebisanovic D Siew LM Leng J Vu M Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Cancer Discov 2015 5 10 1040 1048 10.1158/2159-8290.CD-15-0274 26109333
Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5(10):1040–8.26109333 10.1158/2159-8290.CD-15-0274
57. Marin AM Sanchuki HBS Namur GN Uno M Zanette DL Aoki MN Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer Biomedicines. 2023 11 4 1069 10.3390/biomedicines11041069 37189687
Marin AM, Sanchuki HBS, Namur GN, Uno M, Zanette DL, Aoki MN. Circulating cell-free nucleic acids as biomarkers for diagnosis and prognosis of pancreatic cancer. Biomedicines. 2023;11(4):1069.37189687 10.3390/biomedicines11041069
58. Jones S Zhang X Parsons DW Lin JCH Leary RJ Angenendt P Core signaling pathways in human pancreatic cancers revealed by Global Genomic Analyses Science. 2008 321 5897 1801 6 10.1126/science.1164368 18772397
Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by Global Genomic Analyses. Science. 2008;321(5897):1801–6.18772397 10.1126/science.1164368
59. Saiki Y Horii A Molecular pathology of pancreatic cancer Pathol Int 2014 64 1 10 19 10.1111/pin.12114 24471965
Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int. 2014;64(1):10–9.24471965 10.1111/pin.12114
60. Waddell N Pajic M Patch AM Chang DK Kassahn KS Bailey P Whole genomes redefine the mutational landscape of pancreatic cancer Nature 2015 518 7540 495 501 10.1038/nature14169 25719666
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.25719666 10.1038/nature14169
61. Bailey P Chang DK Nones K Johns AL Patch A-M Gingras M-C Genomic analyses identify molecular subtypes of pancreatic cancer Nature 2016 531 7592 47 52 10.1038/nature16965 26909576
Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.26909576 10.1038/nature16965
62. Pelosi E Castelli G Testa U Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells Biomedicines 2017 5 4 65 10.3390/biomedicines5040065 29156578
Pelosi E, Castelli G, Testa U. Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells. Biomedicines. 2017;5(4):65.29156578 10.3390/biomedicines5040065
63. Notta F Chan-Seng-Yue M Lemire M Li Y Wilson GW Connor AA A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns Nature 2016 538 7625 378 382 10.1038/nature19823 27732578
Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378–82.27732578 10.1038/nature19823
64. Le Calvez-Kelm F Foll M Wozniak MB Delhomme TM Durand G Chopard P KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control Oncotarget 2016 7 48 78827 78840 10.18632/oncotarget.12386 27705932
Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, et al. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7(48):78827–40.27705932 10.18632/oncotarget.12386
65. Conces M Ni Y Bazeley P Patel B Funchain P Carraway HE Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies J Clin Oncol. 2019 37 15 1507 10.1200/JCO.2019.37.15_suppl.1507
Conces M, Ni Y, Bazeley P, Patel B, Funchain P, Carraway HE. Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. J Clin Oncol. 2019;37(15):1507.10.1200/JCO.2019.37.15_suppl.1507
66. Hoermann G Clinical significance of clonal hematopoiesis of indeterminate potential in hematology and cardiovascular disease Diagnostics (Basel). 2022 12 7 1613 10.3390/diagnostics12071613 35885518
Hoermann G. Clinical significance of clonal hematopoiesis of indeterminate potential in hematology and cardiovascular disease. Diagnostics (Basel). 2022;12(7):1613.35885518 10.3390/diagnostics12071613
67. Qi T Pan M Shi H Wang L Bai Y Ge Q Cell-Free DNA Fragmentomics: The Novel Promising Biomarker Int J Mol Sci. 2023 24 2 1503 10.3390/ijms24021503 36675018
Qi T, Pan M, Shi H, Wang L, Bai Y, Ge Q. Cell-free DNA fragmentomics: the novel promising biomarker. Int J Mol Sci. 2023;24(2):1503.36675018 10.3390/ijms24021503
68. Gorgannezhad L Umer M Islam MN Nguyen N-T Shiddiky MJA Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies Lab Chip 2018 18 8 1174 1196 10.1039/C8LC00100F 29569666
Gorgannezhad L, Umer M, Islam MN, Nguyen N-T, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip. 2018;18(8):1174–96.29569666 10.1039/C8LC00100F
69. Newman AM Lovejoy AF Klass DM Kurtz DM Chabon JJ Scherer F Integrated digital error suppression for improved detection of circulating tumor DNA Nat Biotechnol 2016 34 5 547 555 10.1038/nbt.3520 27018799
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–55.27018799 10.1038/nbt.3520
70. Nicholson BD Oke J Virdee PS Harris DA O'Doherty C Park JES Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study Lancet Oncol 2023 24 7 733 743 10.1016/S1470-2045(23)00277-2 37352875
Nicholson BD, Oke J, Virdee PS, Harris DA, O’Doherty C, Park JES, et al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. Lancet Oncol. 2023;24(7):733–43.37352875 10.1016/S1470-2045(23)00277-2
71. García-Ortiz MV Cano-Ramírez P Toledano-Fonseca M Aranda E Rodríguez-Ariza A Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects Biomark Res 2023 11 1 88 10.1186/s40364-023-00528-y 37798621
García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Aranda E, Rodríguez-Ariza A. Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. Biomark Res. 2023;11(1):88.37798621 10.1186/s40364-023-00528-y
72. Xi H Spencer CD Peiyong J Emerging frontiers of cell-free DNA fragmentomics Extracellular Vesicles and Circulating Nucleic Acids 2022 3 4 380 392
Xi H, Spencer CD, Peiyong J. Emerging frontiers of cell-free DNA fragmentomics. Extracellular Vesicles and Circulating Nucleic Acids. 2022;3(4):380–92.
73. Snyder MW Kircher M Hill AJ Daza RM Shendure J Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin Cell 2016 164 1–2 57 68 10.1016/j.cell.2015.11.050 26771485
Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1–2):57–68.26771485 10.1016/j.cell.2015.11.050
74. Mouliere F Chandrananda D Piskorz AM Moore EK Morris J Ahlborn LB Enhanced detection of circulating tumor DNA by fragment size analysis Sci Transl Med 2018 10 466 eaat4921 10.1126/scitranslmed.aat4921 30404863
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.30404863 10.1126/scitranslmed.aat4921
75. Lo KW Lo YM Leung SF Tsang YS Chan LY Johnson PJ Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma Clin Chem 1999 45 8 Pt 1 1292 1294 10.1093/clinchem/45.8.1292 10430801
Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999;45(8 Pt 1):1292–4.10430801 10.1093/clinchem/45.8.1292
76. Kopreski MS Benko FA Kwak LW Gocke CD Detection of tumor messenger RNA in the serum of patients with malignant melanoma Clin Cancer Res 1999 5 8 1961 1965 10473072
Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5(8):1961–5.10473072
77. Heredia-Soto V Rodríguez-Salas N Feliu J Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel). 2021 13 8 1986 10.3390/cancers13081986 33924143
Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice? Cancers (Basel). 2021;13(8):1986.33924143 10.3390/cancers13081986
78. Chen X Ba Y Ma L Cai X Yin Y Wang K Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases Cell Res 2008 18 10 997 1006 10.1038/cr.2008.282 18766170
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.18766170 10.1038/cr.2008.282
79. Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.18663219 10.1073/pnas.0804549105
80. Hunter MP Ismail N Zhang X Aguda BD Lee EJ Yu L Detection of microRNA expression in human peripheral blood microvesicles PLoS ONE 2008 3 11 e3694 10.1371/journal.pone.0003694 19002258
Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008;3(11): e3694.19002258 10.1371/journal.pone.0003694
81. Arroyo JD Chevillet JR Kroh EM Ruf IK Pritchard CC Gibson DF Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma Proc Natl Acad Sci U S A 2011 108 12 5003 5008 10.1073/pnas.1019055108 21383194
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8.21383194 10.1073/pnas.1019055108
82. Vickers KC Palmisano BT Shoucri BM Shamburek RD Remaley AT MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins Nat Cell Biol 2011 13 4 423 433 10.1038/ncb2210 21423178
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33.21423178 10.1038/ncb2210
83. Griffiths-Jones S Grocock RJ van Dongen S Bateman A Enright AJ miRBase: microRNA sequences, targets and gene nomenclature Nucleic Acids Research. 2006 34 suppl_1 D140 D4 10.1093/nar/gkj112 16381832
Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research. 2006;34(suppl_1):D140–4.16381832 10.1093/nar/gkj112
84. Bracken CP Scott HS Goodall GJ A network-biology perspective of microRNA function and dysfunction in cancer Nat Rev Genet 2016 17 12 719 732 10.1038/nrg.2016.134 27795564
Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17(12):719–32.27795564 10.1038/nrg.2016.134
85. O'Brien J Hayder H Zayed Y Peng C Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation Front Endocrinol (Lausanne) 2018 9 402 10.3389/fendo.2018.00402 30123182
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.30123182 10.3389/fendo.2018.00402
86. van Rooij E The art of microRNA research Circ Res 2011 108 2 219 234 10.1161/CIRCRESAHA.110.227496 21252150
van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219–34.21252150 10.1161/CIRCRESAHA.110.227496
87. Cheung KWE Choi SR Lee LTC Lee NLE Tsang HF Cheng YT The potential of circulating cell free RNA as a biomarker in cancer Expert Rev Mol Diagn 2019 19 7 579 590 10.1080/14737159.2019.1633307 31215265
Cheung KWE, Choi SR, Lee LTC, Lee NLE, Tsang HF, Cheng YT, et al. The potential of circulating cell free RNA as a biomarker in cancer. Expert Rev Mol Diagn. 2019;19(7):579–90.31215265 10.1080/14737159.2019.1633307
88. Peng C Wang J Gao W Huang L Liu Y Li X Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer Int J Med Sci 2021 18 3 660 671 10.7150/ijms.52706 33437201
Peng C, Wang J, Gao W, Huang L, Liu Y, Li X, et al. Meta-analysis of the diagnostic performance of circulating MicroRNAs for pancreatic cancer. Int J Med Sci. 2021;18(3):660–71.33437201 10.7150/ijms.52706
89. Schaaij-Visser TB de Wit M Lam SW Jiménez CR The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context Biochim Biophys Acta 2013 1834 11 2242 2258 10.1016/j.bbapap.2013.01.029 23376433
Schaaij-Visser TB, de Wit M, Lam SW, Jiménez CR. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta. 2013;1834(11):2242–58.23376433 10.1016/j.bbapap.2013.01.029
90. Anderson NL Anderson NG The human plasma proteome: history, character, and diagnostic prospects Mol Cell Proteomics 2002 1 11 845 867 10.1074/mcp.R200007-MCP200 12488461
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845–67.12488461 10.1074/mcp.R200007-MCP200
91. Nagayoshi Y Nakamura M Matsuoka K Ohtsuka T Mori Y Kono H Profiling of autoantibodies in sera of pancreatic cancer patients Ann Surg Oncol 2014 21 Suppl 3 S459 S465 10.1245/s10434-014-3574-0 24585405
Nagayoshi Y, Nakamura M, Matsuoka K, Ohtsuka T, Mori Y, Kono H, et al. Profiling of autoantibodies in sera of pancreatic cancer patients. Ann Surg Oncol. 2014;21(Suppl 3):S459–65.24585405 10.1245/s10434-014-3574-0
92. Robinson JL Feizi A Uhlén M Nielsen J A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome Cell Rep 2019 26 10 2622 35.e5 10.1016/j.celrep.2019.02.025 30840886
Robinson JL, Feizi A, Uhlén M, Nielsen J. A systematic investigation of the malignant functions and diagnostic potential of the cancer secretome. Cell Rep. 2019;26(10):2622–35.e5.30840886 10.1016/j.celrep.2019.02.025
93. Veyssière H Bidet Y Penault-Llorca F Radosevic-Robin N Durando X Circulating proteins as predictive and prognostic biomarkers in breast cancer Clin Proteomics 2022 19 1 25 10.1186/s12014-022-09362-0 35818030
Veyssière H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X. Circulating proteins as predictive and prognostic biomarkers in breast cancer. Clin Proteomics. 2022;19(1):25.35818030 10.1186/s12014-022-09362-0
94. Suhre K McCarthy MI Schwenk JM Genetics meets proteomics: perspectives for large population-based studies Nat Rev Genet 2021 22 1 19 37 10.1038/s41576-020-0268-2 32860016
Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large population-based studies. Nat Rev Genet. 2021;22(1):19–37.32860016 10.1038/s41576-020-0268-2
95. O'Neill RS Stoita A Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021 27 26 4045 4087 10.3748/wjg.v27.i26.4045 34326612
O’Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: are we closer to finding the golden ticket? World J Gastroenterol. 2021;27(26):4045–87.34326612 10.3748/wjg.v27.i26.4045
96. Kane LE Mellotte GS Mylod E O'Brien RM O'Connell F Buckley CE Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis Cancer Res Commun 2022 2 10 1229 1243 10.1158/2767-9764.CRC-22-0190 36969742
Kane LE, Mellotte GS, Mylod E, O’Brien RM, O’Connell F, Buckley CE, et al. Diagnostic accuracy of blood-based biomarkers for pancreatic cancer: a systematic review and meta-analysis. Cancer Res Commun. 2022;2(10):1229–43.36969742 10.1158/2767-9764.CRC-22-0190
97. Fauré J Lachenal G Court M Hirrlinger J Chatellard-Causse C Blot B Exosomes are released by cultured cortical neurones Mol Cell Neurosci 2006 31 4 642 648 10.1016/j.mcn.2005.12.003 16446100
Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31(4):642–8.16446100 10.1016/j.mcn.2005.12.003
98. Richards KE Zeleniak AE Fishel ML Wu J Littlepage LE Hill R Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells Oncogene 2017 36 13 1770 1778 10.1038/onc.2016.353 27669441
Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36(13):1770–8.27669441 10.1038/onc.2016.353
99. Ge R Tan E Sharghi-Namini S Asada HH Exosomes in Cancer Microenvironment and Beyond: have we Overlooked these Extracellular Messengers? Cancer Microenvironment 2012 5 3 323 332 10.1007/s12307-012-0110-2 22585423
Ge R, Tan E, Sharghi-Namini S, Asada HH. Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers? Cancer Microenvironment. 2012;5(3):323–32.22585423 10.1007/s12307-012-0110-2
100. Valadi H Ekström K Bossios A Sjöstrand M Lee JJ Lötvall JO Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 2007 9 6 654 659 10.1038/ncb1596 17486113
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.17486113 10.1038/ncb1596
101. Whiteside TL Tumor-Derived Exosomes and Their Role in Cancer Progression Adv Clin Chem 2016 74 103 141 10.1016/bs.acc.2015.12.005 27117662
Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103–41.27117662 10.1016/bs.acc.2015.12.005
102. Armacki M Polaschek S Waldenmaier M Morawe M Ruhland C Schmid R Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice Gastroenterology 2020 159 3 1019 35.e22 10.1053/j.gastro.2020.05.052 32446697
Armacki M, Polaschek S, Waldenmaier M, Morawe M, Ruhland C, Schmid R, et al. Protein kinase D1, reduced in human pancreatic tumors, increases secretion of small extracellular vesicles from cancer cells that promote metastasis to lung in mice. Gastroenterology. 2020;159(3):1019–35.e22.32446697 10.1053/j.gastro.2020.05.052
103. Chang C-H Pauklin S Extracellular vesicles in pancreatic cancer progression and therapies Cell Death Dis 2021 12 11 973 10.1038/s41419-021-04258-7 34671031
Chang C-H, Pauklin S. Extracellular vesicles in pancreatic cancer progression and therapies. Cell Death Dis. 2021;12(11):973.34671031 10.1038/s41419-021-04258-7
104. Ruivo CF Bastos N Adem B Batista I Duraes C Melo CA Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression Gut 2022 71 10 2043 2068 10.1136/gutjnl-2021-324994 35012996
Ruivo CF, Bastos N, Adem B, Batista I, Duraes C, Melo CA, et al. Extracellular vesicles from pancreatic cancer stem cells lead an intratumor communication network (EVNet) to fuel tumour progression. Gut. 2022;71(10):2043–68.35012996 10.1136/gutjnl-2021-324994
105. Zhang YF Zhou YZ Zhang B Huang SF Li PP He XM Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer J Cancer 2019 10 18 4397 4407 10.7150/jca.27590 31413760
Zhang YF, Zhou YZ, Zhang B, Huang SF, Li PP, He XM, et al. Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer. J Cancer. 2019;10(18):4397–407.31413760 10.7150/jca.27590
106. Liu C He D Li L Zhang S Wang L Fan Z Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms Pharmacol Res 2022 183 106364 10.1016/j.phrs.2022.106364 35901939
Liu C, He D, Li L, Zhang S, Wang L, Fan Z, et al. Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms. Pharmacol Res. 2022;183: 106364.35901939 10.1016/j.phrs.2022.106364
107. Melo SA Luecke LB Kahlert C Fernandez AF Gammon ST Kaye J Glypican-1 identifies cancer exosomes and detects early pancreatic cancer Nature 2015 523 7559 177 182 10.1038/nature14581 26106858
Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.26106858 10.1038/nature14581
108. Patton MC Zubair H Khan MA Singh S Singh AP Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival J Cell Biochem 2020 121 1 828 839 10.1002/jcb.29328 31407387
Patton MC, Zubair H, Khan MA, Singh S, Singh AP. Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. J Cell Biochem. 2020;121(1):828–39.31407387 10.1002/jcb.29328
109. Jia E Ren N Shi X Zhang R Yu H Yu F Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis BMC Cancer 2022 22 1 573 10.1186/s12885-022-09463-x 35606727
Jia E, Ren N, Shi X, Zhang R, Yu H, Yu F, et al. Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis. BMC Cancer. 2022;22(1):573.35606727 10.1186/s12885-022-09463-x
110. Chang ST Zahn JM Horecka J Kunz PL Ford JM Fisher GA Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis J Transl Med 2009 7 105 10.1186/1479-5876-7-105 20003342
Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, et al. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009;7:105.20003342 10.1186/1479-5876-7-105
111. Balasenthil S Chen N Lott ST Chen J Carter J Grizzle WE A migration signature and plasma biomarker panel for pancreatic adenocarcinoma Cancer Prev Res (Phila) 2011 4 1 137 149 10.1158/1940-6207.CAPR-10-0025 21071578
Balasenthil S, Chen N, Lott ST, Chen J, Carter J, Grizzle WE, et al. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res (Phila). 2011;4(1):137–49.21071578 10.1158/1940-6207.CAPR-10-0025
112. Brand RE Nolen BM Zeh HJ Allen PJ Eloubeidi MA Goldberg M Serum biomarker panels for the detection of pancreatic cancer Clin Cancer Res 2011 17 4 805 816 10.1158/1078-0432.CCR-10-0248 21325298
Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17(4):805–16.21325298 10.1158/1078-0432.CCR-10-0248
113. Park HD Kang ES Kim JW Lee KT Lee KH Park YS Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma Proteomics 2012 12 23–24 3590 3597 10.1002/pmic.201200101 23065739
Park HD, Kang ES, Kim JW, Lee KT, Lee KH, Park YS, et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics. 2012;12(23–24):3590–7.23065739 10.1002/pmic.201200101
114. Nie S Lo A Wu J Zhu J Tan Z Simeone DM Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis J Proteome Res 2014 13 4 1873 1884 10.1021/pr400967x 24571389
Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, et al. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res. 2014;13(4):1873–84.24571389 10.1021/pr400967x
115. Nolen BM Brand RE Prosser D Velikokhatnaya L Allen PJ Zeh HJ Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study PLoS ONE 2014 9 4 e94928 10.1371/journal.pone.0094928 24747429
Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS ONE. 2014;9(4): e94928.24747429 10.1371/journal.pone.0094928
116. Shaw VE Lane B Jenkinson C Cox T Greenhalf W Halloran CM Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease Mol Cancer 2014 13 114 10.1186/1476-4598-13-114 24884871
Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer. 2014;13:114.24884871 10.1186/1476-4598-13-114
117. Nie S Yin H Tan Z Anderson MA Ruffin MT Simeone DM Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method J Proteome Res 2014 13 12 6058 6066 10.1021/pr500934u 25393578
Nie S, Yin H, Tan Z, Anderson MA, Ruffin MT, Simeone DM, et al. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method. J Proteome Res. 2014;13(12):6058–66.25393578 10.1021/pr500934u
118. Tang H Singh S Partyka K Kletter D Hsueh P Yadav J Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A Mol Cell Proteomics 2015 14 5 1323 1333 10.1074/mcp.M114.047837 25733690
Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, et al. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. Mol Cell Proteomics. 2015;14(5):1323–33.25733690 10.1074/mcp.M114.047837
119. Liu X Zheng W Wang W Shen H Liu L Lou W A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline Br J Cancer 2017 117 12 1846 1854 10.1038/bjc.2017.365 29123261
Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, et al. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 2017;117(12):1846–54.29123261 10.1038/bjc.2017.365
120. Mattila N Seppänen H Mustonen H Przybyla B Haglund C Lassila R Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma Clin Appl Thromb Hemost 2018 24 8 1267 1275 10.1177/1076029618779133 29865859
Mattila N, Seppänen H, Mustonen H, Przybyla B, Haglund C, Lassila R. Preoperative biomarker panel, including fibrinogen and FVIII, improves diagnostic accuracy for pancreatic ductal adenocarcinoma. Clin Appl Thromb Hemost. 2018;24(8):1267–75.29865859 10.1177/1076029618779133
121. Peng HY Chang MC Hu CM Yang HI Lee WH Chang YT Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer Ann Surg Oncol 2019 26 3 807 814 10.1245/s10434-018-07109-6 30569296
Peng HY, Chang MC, Hu CM, Yang HI, Lee WH, Chang YT. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer. Ann Surg Oncol. 2019;26(3):807–14.30569296 10.1245/s10434-018-07109-6
122. Staal B Liu Y Barnett D Hsueh P He Z Gao C The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis Clin Cancer Res 2019 25 9 2745 2754 10.1158/1078-0432.CCR-18-3310 30617132
Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, et al. The sTRA Plasma biomarker: blinded validation of improved accuracy over CA19-9 in pancreatic cancer diagnosis. Clin Cancer Res. 2019;25(9):2745–54.30617132 10.1158/1078-0432.CCR-18-3310
123. Zhou Q Andersson R Hu D Bauden M Sasor A Bygott T Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis Transl Res 2019 212 67 79 10.1016/j.trsl.2019.06.003 31295437
Zhou Q, Andersson R, Hu D, Bauden M, Sasor A, Bygott T, et al. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Transl Res. 2019;212:67–79.31295437 10.1016/j.trsl.2019.06.003
124. Kim H, Kang KN, Shin YS, Byun Y, Han Y, Kwon W, et al. Biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(6):1443. 10.3390/cancers12061443.
125. Kim Y Yeo I Huh I Kim J Han D Jang JY Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer Clin Cancer Res 2021 27 8 2236 2245 10.1158/1078-0432.CCR-20-3929 33504556
Kim Y, Yeo I, Huh I, Kim J, Han D, Jang JY, et al. Development and multiple validation of the protein multi-marker panel for diagnosis of pancreatic cancer. Clin Cancer Res. 2021;27(8):2236–45.33504556 10.1158/1078-0432.CCR-20-3929
126. Mehta S Bhimani N Gill AJ Samra JS Sahni S Mittal A Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas Front Oncol 2021 11 708963 10.3389/fonc.2021.708963 34290990
Mehta S, Bhimani N, Gill AJ, Samra JS, Sahni S, Mittal A. Serum biomarker panel for diagnosis and prognosis of pancreatic ductal adenocarcinomas. Front Oncol. 2021;11: 708963.34290990 10.3389/fonc.2021.708963
127. Nené NR Ney A Nazarenko T Blyuss O Johnston HE Whitwell HJ Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning Commun Med (Lond) 2023 3 1 10 10.1038/s43856-023-00237-5 36670203
Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. Commun Med (Lond). 2023;3(1):10.36670203 10.1038/s43856-023-00237-5
128. Cao H Zhu L Li L Wang W Niu X Serum CA724 has no diagnostic value for gastrointestinal tumors Clin Exp Med 2023 23 6 2433 2442 10.1007/s10238-023-01025-0 36920593
Cao H, Zhu L, Li L, Wang W, Niu X. Serum CA724 has no diagnostic value for gastrointestinal tumors. Clin Exp Med. 2023;23(6):2433–42.36920593 10.1007/s10238-023-01025-0
129. Jang SI Lee HK Chang EJ Kim S Kim SY Hong IY Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing Cancer Immunol Immunother 2023 72 8 2757 2768 10.1007/s00262-023-03458-8 37165046
Jang SI, Lee HK, Chang EJ, Kim S, Kim SY, Hong IY, et al. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing. Cancer Immunol Immunother. 2023;72(8):2757–68.37165046 10.1007/s00262-023-03458-8
130. Makawita S Dimitromanolakis A Soosaipillai A Soleas I Chan A Gallinger S Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 BMC Cancer. 2013 13 404 10.1186/1471-2407-13-404 24007603
Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, et al. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer. 2013;13:404.24007603 10.1186/1471-2407-13-404
131. Tang H Partyka K Hsueh P Sinha JY Kletter D Zeh H Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9 Cell Mol Gastroenterol Hepatol 2016 2 2 201 21.e15 26998508
Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, et al. Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell Mol Gastroenterol Hepatol. 2016;2(2):201–21.e15.26998508
132. Yoneyama T Ohtsuki S Honda K Kobayashi M Iwasaki M Uchida Y Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics PLoS ONE 2016 11 8 e0161009 10.1371/journal.pone.0161009 27579675
Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS ONE. 2016;11(8): e0161009.27579675 10.1371/journal.pone.0161009
133. Capello M Bantis LE Scelo G Zhao Y Li P Dhillon DS Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer J Natl Cancer Inst. 2017 109 4 djw266 10.1093/jnci/djw266 28376157
Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, et al. Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer. J Natl Cancer Inst. 2017;109(4):djw266.28376157 10.1093/jnci/djw266
134. Balasenthil S Huang Y Liu S Marsh T Chen J Stass SA A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer J Natl Cancer Inst. 2017 109 8 djw341 10.1093/jnci/djw341 28376184
Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, et al. A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. J Natl Cancer Inst. 2017;109(8):djw341.28376184 10.1093/jnci/djw341
135. Kaur S Smith LM Patel A Menning M Watley DC Malik SS A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study Am J Gastroenterol 2017 112 1 172 183 10.1038/ajg.2016.482 27845339
Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, et al. A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: a multicenter study. Am J Gastroenterol. 2017;112(1):172–83.27845339 10.1038/ajg.2016.482
136. Kim J Bamlet WR Oberg AL Chaffee KG Donahue G Cao XJ Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19–9 blood markers Sci Transl Med. 2017 9 398 eaah5583 10.1126/scitranslmed.aah5583 28701476
Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19–9 blood markers. Sci Transl Med. 2017;9(398):eaah5583.28701476 10.1126/scitranslmed.aah5583
137. Park J Choi Y Namkung J Yi SG Kim H Yu J Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel Oncotarget 2017 8 54 93117 93130 10.18632/oncotarget.21861 29190982
Park J, Choi Y, Namkung J, Yi SG, Kim H, Yu J, et al. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget. 2017;8(54):93117–30.29190982 10.18632/oncotarget.21861
138. Resovi A Bani MR Porcu L Anastasia A Minoli L Allavena P Soluble stroma-related biomarkers of pancreatic cancer EMBO Mol Med. 2018 10 8 e8741 10.15252/emmm.201708741 29941541
Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, et al. Soluble stroma-related biomarkers of pancreatic cancer. EMBO Mol Med. 2018;10(8):e8741.29941541 10.15252/emmm.201708741
139. Dong D Jia L Zhang L Ma N Zhang A Zhou Y Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer Cancer Sci. 2018 109 9 2841 51 10.1111/cas.13712 29945294
Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, et al. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018;109(9):2841–51.29945294 10.1111/cas.13712
140. Song J Sokoll LJ Pasay JJ Rubin AL Li H Bach DM Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer Cancer Epidemiol Biomarkers Prev 2019 28 1 174 182 10.1158/1055-9965.EPI-18-0483 30333219
Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, et al. Identification of serum biomarker panels for the early detection of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(1):174–82.30333219 10.1158/1055-9965.EPI-18-0483
141. Jahan R Ganguly K Smith LM Atri P Carmicheal J Sheinin Y Trefoil factor(s) and CA19.9: a promising panel for early detection of pancreatic cancer EBioMedicine. 2019 42 375 85 10.1016/j.ebiom.2019.03.056 30956167
Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, et al. Trefoil factor(s) and CA19.9: a promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375–85.30956167 10.1016/j.ebiom.2019.03.056
142. Zhang J Wang Y Zhao T Li Y Tian L Zhao J Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer World J Surg Oncol 2020 18 1 31 10.1186/s12957-020-1809-z 32028958
Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J, et al. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol. 2020;18(1):31.32028958 10.1186/s12957-020-1809-z
143. Peng H Pan S Yan Y Brand RE Petersen GM Chari ST Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients Cancers (Basel). 2020 12 6 1534 10.3390/cancers12061534 32545216
Peng H, Pan S, Yan Y, Brand RE, Petersen GM, Chari ST, et al. Systemic proteome alterations linked to early stage pancreatic cancer in diabetic patients. Cancers (Basel). 2020;12(6):1534.32545216 10.3390/cancers12061534
144. Choi YJ Yoon W Lee A Han Y Byun Y Kang JS Diagnostic model for pancreatic cancer using a multi-biomarker panel Ann Surg Treat Res 2021 100 3 144 153 10.4174/astr.2021.100.3.144 33748028
Choi YJ, Yoon W, Lee A, Han Y, Byun Y, Kang JS, et al. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Ann Surg Treat Res. 2021;100(3):144–53.33748028 10.4174/astr.2021.100.3.144
145. Lee DH Yoon W Lee A Han Y Byun Y Kang JS Multi-biomarker panel prediction model for diagnosis of pancreatic cancer J Hepatobiliary Pancreat Sci 2023 30 1 122 132 10.1002/jhbp.986 33991409
Lee DH, Yoon W, Lee A, Han Y, Byun Y, Kang JS, et al. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Sci. 2023;30(1):122–32.33991409 10.1002/jhbp.986
146. Song J Sokoll LJ Chan DW Zhang Z Validation of Serum Biomarkers That Complement CA19–9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays Biomedicines. 2021 9 12 1897 10.3390/biomedicines9121897 34944713
Song J, Sokoll LJ, Chan DW, Zhang Z. Validation of serum biomarkers that complement CA19–9 in detecting early pancreatic cancer using electrochemiluminescent-based multiplex immunoassays. Biomedicines. 2021;9(12):1897.34944713 10.3390/biomedicines9121897
147. Hinestrosa JP Kurzrock R Lewis JM Schork NJ Schroeder G Kamat AM Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test Commun Med (Lond) 2022 2 29 10.1038/s43856-022-00088-6 35603292
Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond). 2022;2:29.35603292 10.1038/s43856-022-00088-6
148. Firpo MA Boucher KM Bleicher J Khanderao GD Rosati A Poruk KE Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma JCO Clin Cancer Inform 2023 7 e2200160 10.1200/CCI.22.00160 36913644
Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, et al. Multianalyte serum biomarker panel for early detection of pancreatic adenocarcinoma. JCO Clin Cancer Inform. 2023;7: e2200160.36913644 10.1200/CCI.22.00160
149. Byeon S McKay MJ Molloy MP Gill AJ Samra JS Mittal A Novel serum protein biomarker panel for early diagnosis of pancreatic cancer Int J Cancer. 2024 155 365 371 10.1002/ijc.34928 38519999
Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, et al. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Int J Cancer. 2024;155:365–71.38519999 10.1002/ijc.34928
150. Yi JM Guzzetta AA Bailey VJ Downing SR Van Neste L Chiappinelli KB Novel methylation biomarker panel for the early detection of pancreatic cancer Clin Cancer Res 2013 19 23 6544 6555 10.1158/1078-0432.CCR-12-3224 24088737
Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19(23):6544–55.24088737 10.1158/1078-0432.CCR-12-3224
151. Eissa MAL Lerner L Abdelfatah E Shankar N Canner JK Hasan NM Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood Clin Epigenetics 2019 11 1 59 10.1186/s13148-019-0650-0 30953539
Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11(1):59.30953539 10.1186/s13148-019-0650-0
152. Ganepola GA Rutledge JR Suman P Yiengpruksawan A Chang DH Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer World J Gastrointest Oncol 2014 6 1 22 33 10.4251/wjgo.v6.i1.22 24578785
Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014;6(1):22–33.24578785 10.4251/wjgo.v6.i1.22
153. Makler A Asghar W Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study Int J Mol Sci. 2023 24 6 5081 10.3390/ijms24065081 36982154
Makler A, Asghar W. Exosomal miRNA biomarker panel for pancreatic ductal adenocarcinoma detection in patient plasma: a pilot study. Int J Mol Sci. 2023;24(6):5081.36982154 10.3390/ijms24065081
154. Yang Z Huang J Wu X Zhou Y Tang Y Zhu Y Contribution of a Circulating 2'-O-methylated MicroRNA Panel to the Diagnosis of Pancreatic Ductal Adenocarcinoma J Cancer 2024 15 6 1583 1592 10.7150/jca.91716 38370369
Yang Z, Huang J, Wu X, Zhou Y, Tang Y, Zhu Y, et al. Contribution of a circulating 2’-O-methylated MicroRNA panel to the diagnosis of pancreatic ductal adenocarcinoma. J Cancer. 2024;15(6):1583–92.38370369 10.7150/jca.91716
155. Madhavan B Yue S Galli U Rana S Gross W Müller M Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity Int J Cancer 2015 136 11 2616 2627 10.1002/ijc.29324 25388097
Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–27.25388097 10.1002/ijc.29324
156. Yuan W Tang W Xie Y Wang S Chen Y Qi J New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer Oncotarget 2016 7 48 80033 80045 10.18632/oncotarget.12406 27713117
Yuan W, Tang W, Xie Y, Wang S, Chen Y, Qi J, et al. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer. Oncotarget. 2016;7(48):80033–45.27713117 10.18632/oncotarget.12406
157. Berger AW Schwerdel D Reinacher-Schick A Uhl W Algül H Friess H A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer Theranostics 2019 9 5 1280 1287 10.7150/thno.29247 30867830
Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, et al. A blood-based multi marker assay supports the differential diagnosis of early-stage pancreatic cancer. Theranostics. 2019;9(5):1280–7.30867830 10.7150/thno.29247
158. Reese M Flammang I Yang Z Dhayat SA Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma Cancers (Basel). 2020 12 1 197 10.3390/cancers12010197 31941049
Reese M, Flammang I, Yang Z, Dhayat SA. Potential of exosomal microRNA-200b as liquid biopsy marker in pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(1):197.31941049 10.3390/cancers12010197
159. Chen J Wang H Zhou L Liu Z Tan X A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer J Clin Lab Anal 2022 36 5 e24341 10.1002/jcla.24341 35334495
Chen J, Wang H, Zhou L, Liu Z, Tan X. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer. J Clin Lab Anal. 2022;36(5): e24341.35334495 10.1002/jcla.24341
160. Cohen JD Javed AA Thoburn C Wong F Tie J Gibbs P Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers Proc Natl Acad Sci U S A 2017 114 38 10202 10207 10.1073/pnas.1704961114 28874546
Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114(38):10202–7.28874546 10.1073/pnas.1704961114
161. Fahrmann JF Bantis LE Capello M Scelo G Dennison JB Patel N A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer J Natl Cancer Inst 2019 111 4 372 379 10.1093/jnci/djy126 30137376
Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, et al. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. J Natl Cancer Inst. 2019;111(4):372–9.30137376 10.1093/jnci/djy126
162. Nakamura K Zhu Z Roy S Jun E Han H Munoz RM An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study Gastroenterology 2022 163 5 1252 66.e2 10.1053/j.gastro.2022.06.090 35850192
Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a multicenter cohort study. Gastroenterology. 2022;163(5):1252–66.e2.35850192 10.1053/j.gastro.2022.06.090
163. Zhao R Ren S Li C Guo K Lu Z Tian L Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study Cancer Med 2023 12 4 5158 5171 10.1002/cam4.5296 36161527
Zhao R, Ren S, Li C, Guo K, Lu Z, Tian L, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med. 2023;12(4):5158–71.36161527 10.1002/cam4.5296
164. Xu C, Jun E, Okugawa Y, Toiyama Y, Borazanci E, Bolton J, et al. A circulating panel of circRNA biomarkers for the noninvasive and early detection of pancreatic ductal adenocarcinoma. Gastroenterology. 2023;166(1)178–90.E16. 10.1053/j.gastro.2023.09.050.
165. He J Long J Zhai C Xu J Bao K Su W Codetection of Proteins and RNAs on Extracellular Vesicles for Pancreatic Cancer Early Diagnosis Anal Chem 2024 96 17 6618 6627 10.1021/acs.analchem.3c05858 38626343
He J, Long J, Zhai C, Xu J, Bao K, Su W, et al. Codetection of proteins and RNAs on extracellular vesicles for pancreatic cancer early diagnosis. Anal Chem. 2024;96(17):6618–27.38626343 10.1021/acs.analchem.3c05858
166. Kim S Park BK Seo JH Choi J Choi JW Lee CK Carbohydrate antigen 19–9 elevation without evidence of malignant or pancreatobiliary diseases Sci Rep 2020 10 1 8820 10.1038/s41598-020-65720-8 32483216
Kim S, Park BK, Seo JH, Choi J, Choi JW, Lee CK, et al. Carbohydrate antigen 19–9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep. 2020;10(1):8820.32483216 10.1038/s41598-020-65720-8
167. Prior IA Hood FE Hartley JL The Frequency of Ras Mutations in Cancer Can Res 2020 80 14 2969 2974 10.1158/0008-5472.CAN-19-3682
Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Can Res. 2020;80(14):2969–74.10.1158/0008-5472.CAN-19-3682
168. Cohen JD Li L Wang Y Thoburn C Afsari B Danilova L Detection and localization of surgically resectable cancers with a multi-analyte blood test Science 2018 359 6378 926 930 10.1126/science.aar3247 29348365
Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–30.29348365 10.1126/science.aar3247
169. Jamshidi A Liu MC Klein EA Venn O Hubbell E Beausang JF Evaluation of cell-free DNA approaches for multi-cancer early detection Cancer Cell 2022 40 12 1537 49.e12 10.1016/j.ccell.2022.10.022 36400018
Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022;40(12):1537–49.e12.36400018 10.1016/j.ccell.2022.10.022
170. Liu MC Oxnard GR Klein EA Swanton C Seiden MV Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA Ann Oncol 2020 31 6 745 759 10.1016/j.annonc.2020.02.011 33506766
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–59.33506766 10.1016/j.annonc.2020.02.011
171. Klein EA Richards D Cohn A Tummala M Lapham R Cosgrove D Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set Ann Oncol 2021 32 9 1167 1177 10.1016/j.annonc.2021.05.806 34176681
Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–77.34176681 10.1016/j.annonc.2021.05.806
172. Schrag D Beer TM McDonnell CH 3rd Nadauld L Dilaveri CA Reid R Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study Lancet 2023 402 10409 1251 1260 10.1016/S0140-6736(23)01700-2 37805216
Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251–60.37805216 10.1016/S0140-6736(23)01700-2
173. Gao Q Lin YP Li BS Wang GQ Dong LQ Shen BY Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies Ann Oncol 2023 34 5 486 495 10.1016/j.annonc.2023.02.010 36849097
Gao Q, Lin YP, Li BS, Wang GQ, Dong LQ, Shen BY, et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Ann Oncol. 2023;34(5):486–95.36849097 10.1016/j.annonc.2023.02.010
174. Hartwig W Hackert T Hinz U Gluth A Bergmann F Strobel O Pancreatic cancer surgery in the new millennium: better prediction of outcome Ann Surg 2011 254 2 311 319 10.1097/SLA.0b013e31821fd334 21606835
Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254(2):311–9.21606835 10.1097/SLA.0b013e31821fd334
175. Cameron JL Riall TS Coleman J Belcher KA One thousand consecutive pancreaticoduodenectomies Ann Surg 2006 244 1 10 15 10.1097/01.sla.0000217673.04165.ea 16794383
Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.16794383 10.1097/01.sla.0000217673.04165.ea
176. Yang R Du Y Zhang M Liu Y Feng H Liu R Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer Front Immunol 2023 14 1249731 10.3389/fimmu.2023.1249731 37928544
Yang R, Du Y, Zhang M, Liu Y, Feng H, Liu R, et al. Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer. Front Immunol. 2023;14:1249731.37928544 10.3389/fimmu.2023.1249731
177. Lampignano R Neumann MHD Weber S Kloten V Herdean A Voss T Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows Clin Chem 2020 66 1 149 160 10.1373/clinchem.2019.306837 31628139
Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, et al. Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (Pre)analytical work flows. Clin Chem. 2020;66(1):149–60.31628139 10.1373/clinchem.2019.306837
178. Kloten V Neumann MHD Di Pasquale F Sprenger-Haussels M Shaffer JM Schlumpberger M Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows Clin Chem 2019 65 9 1132 1140 10.1373/clinchem.2019.303271 31235535
Kloten V, Neumann MHD, Di Pasquale F, Sprenger-Haussels M, Shaffer JM, Schlumpberger M, et al. Multicenter evaluation of circulating plasma MicroRNA extraction technologies for the development of clinically feasible reverse transcription quantitative PCR and next-generation sequencing analytical work flows. Clin Chem. 2019;65(9):1132–40.31235535 10.1373/clinchem.2019.303271
179. Neves RPL Ammerlaan W Andree KC Bender S Cayrefourcq L Driemel C Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID Clin Chem 2021 67 4 631 641 10.1093/clinchem/hvaa322 33491069
Neves RPL, Ammerlaan W, Andree KC, Bender S, Cayrefourcq L, Driemel C, et al. Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. Clin Chem. 2021;67(4):631–41.33491069 10.1093/clinchem/hvaa322
180. PANCAID Consortium. PANcreatic CAncer Initial Detection via liquid biopsy (PANCAID). 2023. Available from: https://pancaid-project.eu.
181. Pantel K Alix-Panabières C Liquid biopsy and minimal residual disease - latest advances and implications for cure Nat Rev Clin Oncol 2019 16 7 409 424 10.1038/s41571-019-0187-3 30796368
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.30796368 10.1038/s41571-019-0187-3
182. Pascual J Attard G Bidard FC Curigliano G De Mattos-Arruda L Diehn M ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group Ann Oncol 2022 33 8 750 768 10.1016/j.annonc.2022.05.520 35809752
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750–68.35809752 10.1016/j.annonc.2022.05.520
183. Pantel K Lindbjerg Andersen C Schuuring E Malats N Heitzer E Vat L 237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes Ann Oncol. 2023 34 S276 S7 10.1016/j.annonc.2023.09.2960
Pantel K, Lindbjerg Andersen C, Schuuring E, Malats N, Heitzer E, Vat L, et al. 237TiP GUIDE.MRD: a Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes. Ann Oncol. 2023;34:S276–7.10.1016/j.annonc.2023.09.2960
